

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033231
Article Type:	Research
Date Submitted by the Author:	01-Aug-2019
Complete List of Authors:	Stedman, Mike; Res Consortium Lunt, Mark; University of Manchester, ARC Epidemiology Unit Davies, Mark; Res Consortium Livingston, Mark; Walsall Healthcare NHS Trust, Clinical Biochemistry Duff, Christopher; University Hospitals of North Midlands NHS Trust, Department of Clinical Biochemistry Fryer, Anthony; Keele University, Institute for Science & Technology in Medicine Anderson, Simon; University of the West Indies Cave Hill Campus, The George Alleyne Chronic Disease Research Centre Gadsby, Roger ; University of Warwick Warwick Medical School Gibson, Martin; Salford Royal Hospital, Endocrinology and Diabetes Rayman, Gerry; Ipswich Hospital NHS Trust, The Ipswich Diabetes Centre and Research Unit Heald, Adrian; Leighton Hospital, Medicine
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, HEALTH ECONOMICS, PUBLIC HEALTH, Hospital

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2
5 2 diabetes (T2DM) compared to the non-diabetes population: a detailed
6 3 economic evaluation
7 4
8 5
9 6

10 7 Mike Stedman¹, Mark Lunt², Mark Davies¹, Mark Livingston³, Christopher J Duff^{4,5},
11 8 Anthony Fryer^{4,5}, Simon Anderson², Roger Gadsby⁶, J Martin Gibson², Gerry
12 9 Rayman⁷, Adrian Heald^{1,8}
13 10

14 11
15 12
16 13
17 14 ¹Res Consortium, Andover, Hampshire; ²The School of Medicine and Manchester
18 15 Academic Health Sciences Centre, University of Manchester, Manchester;
19 16 ³Department of Clinical Biochemistry, Black Country Pathology Services, Walsall
20 17 Manor Hospital, Walsall; ⁴Department of Clinical Biochemistry, University Hospitals
21 18 of North Midlands NHS Trust, Stoke on Trent; ⁵Institute for Science and Technology
22 19 in Medicine, Keele University; ⁶Warwick Medical School, University of Warwick,
23 20 ⁷Department of Diabetes and Endocrinology, Ipswich General Hospital, ⁸Department
24 21 of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK
25 22
26 23
27 24

28 25 Corresponding author: Dr Adrian Heald
29 26 Department of Diabetes and Endocrinology,
30 27 Salford Royal Hospital, Salford, UK.
31 28 M6 8HD
32 29

33 30 Telephone: +44 161 206 5157
34 31

35 32 Email: adrian.heald@manchester.ac.uk
36 33

37 34 Manuscript word count (main text): 3998
38 35
39 36

40 37 Key words: Type 2 diabetes, Type 1 diabetes, Hospital, HES, Cost, GP practice
41 38
42 39
43 40
44 41
45 42
46 43
47 44
48 45
49 46
50 47
51 48
52 49
53 50
54 51
55 52
56 53
57 54
58 55
59 56
60 57

1
2
3 51
4 52 Key messages:
5 53
6 54

- 7 54 • Our aim was to more exactly quantify the net impact of diabetes on the
8 55 different aspects of healthcare provision in hospitals in England.
9
10 56 • The study captured around 90% of the hospital activity and £36 billion/year of
11 57 hospital spend.
12
13 58 • Once the normal expected costs including the older age of T2DM hospital
14 59 attenders are allowed for this fell to £3.0 billion/year or 8% of the total
15 60 captured secondary care costs. This equates to £560/non-diabetes person
16 61 compared to £3,280/person with T1DM and £1,686/person with T2DM.
17
18 62 • There are still opportunities to reduce potential future additional costs further
19 63 through increased investment in local services and medication for diabetes
20 64 treatment.
21
22 65
23 66

24 67 Article Summary:

25 68 Strengths and Limitations of the Study
26 69

- 27 70 • *In relation to strengths*, we were able to look at national level data across
28 71 nearly 5500 GP practices in relation to hospital activity. The analysis covered
29 72 more than 90% of hospital costs on England.
30
31 73 • *In relation to limitations*, a caveat in any conclusions drawn is that our findings
32 74 are based on association. Also inherent in this real world analysis
33 75 methodology are potential confounding factors which are inherent in any
34 76 retrospective study. Nevertheless our design was such as to minimise the
35 77 potential impact of such factors.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

81 **Abstract**

82 Objectives

83 Other than age, diabetes is the largest contributor to overall health care costs and
84 reduced life expectancy in Europe. The aim of this paper is to more exactly quantify
85 the net impact of diabetes on different aspects of healthcare provision in hospitals in
86 England.

87 Setting

88 NHS Digital Hospital Episode Statistics (HES) in England was combined with the
89 National Diabetes Audit (NDA) to provide the total number in practice of people with
90 T1DM/T2DM.

92 Outcome measures

93 We compared differences between T1DM/T2DM and non-diabetes individuals in
94 relation to hospital activity.

96 Results

97 The study captured 90% of hospital activity and £36 billion/year of hospital spend.
98 The NDA Register showed that out of a total reported population of 58 million, 2.9
99 million (6.5%) had T2DM and 240 thousand (0.6%) had T1DM. Bed day analysis
100 showed 17% of beds are occupied by T2DM and 3% by T1DM.

101 Overall cost of hospital care for people with diabetes is £5.5 billion/year. Once the
102 normal expected costs including the older age of T2DM hospital attenders are
103 allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care
104 costs. This equates to £560/non-diabetes person compared to £3,280/person with
105 T1DM and £1,686/person with T2DM.

106 For people with diabetes the net excess impact on non-elective/emergency work is
107 £1.2 billion with additional estimated diabetes related A&E attendances at 440,000
108 costing the NHS £70 million/year.

109 T1DM individuals required five times more secondary care support than non-
110 diabetes individuals. T2DM individuals, even allowing for the age, require twice as
111 much support as non-diabetes individuals.

1
2
3 112 Conclusions
4

5 113 There are still opportunities to reduce potential future additional costs through
6
7 114 increased investment in local services and medication for diabetes treatment.

8 115 Supporting patients in diabetes management could significantly reduce hospital
9
10 116 activity including emergency bed occupancy of people with T1DM/T2DM.
11

12 117
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

118 Introduction

119
120 Other than age, diabetes is the largest contributor to overall health care costs and
121 reduced life expectancy in Europe (1). People with Type 1 (T1DM) and Type 2
122 (T2DM) diabetes require much higher levels of hospital support than their non-
123 diabetes counterparts. Health care provision in hospital can be broken down into four
124 main areas: 1) planned/elective including day-case admissions (Planned), 2)
125 emergency/non-elective admissions (Emergency), 3) accident & emergency (A&E)
126 attendances and 4) outpatient consultations/attendances (Outpatient). Each of these
127 different classes must be managed appropriately by clinicians and hospital
128 administrators and the relevance of diabetes to this planning may be different.

129
130 With regard to hospital bed occupancy, the National Diabetes Inpatient Audit (2) has
131 shown that 18% of all hospital beds on any days are occupied by people who have a
132 diagnosis of diabetes (2) compared to a 7% prevalence of all diabetes in the adult
133 population of England. This may significantly overstate the impact of the condition as
134 over 90% of people with diabetes have T2DM, which generally occurs much later in
135 life so that the cohort is significantly older than the general population – as such their
136 normal healthcare requirements would increase significantly with age.

137
138 NHS Digital publish the general practitioner (GP) practice patient register split into age
139 groups and can provide practice level extracts from hospital episode statistics (HES)
140 of the amount of different practice activities for people who have a recorded
141 diagnosis of T1DM or T2DM and those that do not have such a diagnosis (3). The
142 National Diabetes Audit publish the numbers and ages of people with either T1DM or
143 T2DM in each practice (4) also split into age groups. Other practice characteristics
144 such as ethnicity, social deprivation, location, are also publicly available (5).

145
146 The NHS in England publishes significant amount of data at GP practice level and
147 we have previously described the impact a variety of population, service and
148 prescribing factors on outcomes (6,7). It was felt that this approach could be used to
149 quantify and so adjust for the effect of age on different services that are provided in
150 hospital to T2DM individuals and therefore achieve a much more accurate evaluation

1
2
3 151 of the actual net cost of diabetes, including all associated comorbidities to the health
4 152 service.

5
6 153

7 8 9 154 **Aims**

10
11 155 The aim of this paper is to more exactly quantify the net impact of diabetes on the
12 156 different aspects of healthcare provision in hospitals in England.

13
14 157

15
16 158 At GP practice level, we took the allocation of the different elements of hospital costs
17 159 associated with the diagnosis of either T2DM or T1DM while adjusting for difference
18 160 in T2DM age profile from the general population. We wished to use this analysis to
19 161 provide a clearer focus for diabetes services to determine which elements of care
20 162 they can focus on in order to improve outcomes. Specifically we compared
21 163 differences between T1DM/T2DM and non-diabetes individuals in relation to hospital
22 164 activity.

23
24 165

25
26 166

27 28 29 167 **Methods**

30
31 168 Individual patients who had a diagnosis of either T1DM or T2DM and their age and
32 169 practice code were identified within the NHS Digital Hospital Episode Statistics
33 170 (HES) data for 2016_17 and 2017_18. The sum of annual activity of the different
34 171 services, including emergency, elective, A&E and outpatient care, was then
35 172 extracted from the NHS Digital HES for each general practice for all those patients
36 173 with diagnosis of T1DM or T2DM and the non-diabetes individuals. Emergency and
37 174 elective activity were shown as totals for number of unique patients, admissions,
38 175 overall bed-days and total national tariff charged, while the number of unique
39 176 patients and total attendances were provided for outpatient and A&E activity. The
40 177 completeness of data was checked by looking at the national totals for the year
41 178 reported within the reference costs.

42
43 179

44
45 180 The actual total population of T1DM and T2DM individuals and their age groups at
46 181 GP practice level was taken from NHS Digital National Diabetes Audit (4). Public
47 182 Health England publishes the patient numbers and age profile of each GP practice

1
2
3 183 from this total. The ge profile for non-diabetes patients was calculated by subtracting
4 184 the total diabetes population.
5
6
7 185

8 186 The demographic and locational data for each practice including social deprivation,
9 187 population density (urban/rural), Latitude (Northerliness) were taken from the Office
10 188 of National Statistic (ONS) (5). The % minority ethnicity was also determined.
11
12
13 189

14
15 190 The total overall hospital costs for each practice in each of the three classes (T1DM,
16 191 T2DM, and non-diabetes) were calculated by adding the provided total elective &
17 192 non-elective tariff charges to the Outpatient and Accident & Emergency attendances
18 193 each multiplied by the national overall average cost / attendance taken from the
19 194 2017-18 national reference costs.
20
21
22
23 195

24
25 196 The number of practices included in the study was limited to those for which all the
26 197 data sets were available plus if there were more than 200 T2DM patients or more
27 198 than 20 T1DM patients on their register (5468 GP practices).
28
29
30 199

31
32 200 Practices that identify people earlier in the course of their T2DM increase their
33 201 numbers and pro rata this reduces the associated costs/person. In order to include
34 202 this a "T2DM %case identification" factor was calculated. Our statistical model took
35 203 account of this and linked the actual recorded T2DM register as % of total practice
36 204 population to the practice age, gender, ethnicity, social disadvantage, latitude and
37 205 main long-term condition disease prevalence. Based on this statistical model an
38 206 expected level of T2DM could be predicted. The difference between the predicted
39 207 and actual T2DM prevalence was taken as the local practice % case identification.
40 208 This factor was not required for T1DM as the onset of that condition is much more
41 209 clearly delineated, so all people with this condition can be more clearly identified.
42
43
44
45 210

51 211 Patient and Public Involvement Statement

52 212 It was not appropriate or possible to involve patients or the public in this work given
53 213 that we used general practice level summated data and related hospital outcome
54 214 statistics.
55
56
57 215

216 Statistics

217
218 A stepwise multiple regression model was created linking each activity of each class
219 of hospital activity for T1DM and T2DM at GP practice level to the:

- 220 • Same measure for the non-diabetes population
- 221 • % of non-diabetes population age >75
- 222 • % of either T1DM or T2DM
- 223 • % case Identification (T2DM)
- 224 • Population Density (pop/sq km)
- 225 • % Black and Minority Ethnicity (BME)
- 226 • Practice Size
- 227 • % Prevalence of T2DM
- 228 • Latitude

229
230 In order to remove the effect of age difference between T2DM and non-diabetes
231 population on the cost impact of diabetes, the T2DM % on patients over 75 was
232 adjusted to the level of the non-diabetes population providing a “net” disease effect
233 on each of the activities and cost levels including:

- 234
235 • Overall Costs
- 236 • Emergency Admissions, Bed days & Tariff
- 237 • Elective Admissions, Day case, Bed days & Tariff
- 238 • A&E Attendances
- 239 • Outpatient Attendances

240
241 In order to translate these national level findings to local populations, the relative
242 activity for T1DM and T2DM was calculated as a ratio to the non-diabetes activity.

244 Results

245 The study (See Table 1) captured around 90% of the hospital activity data for
246 England in 2017/18. The missing 10% could be explained by difference in definitions
247 between the different analyses (i.e. outpatient attendances and episodes which
248 include more than one attendance). The tariff difference between reference known

249 costs of hospital T1DM/T2DM management and extracted HES of just under
 250 £7billion could relate to other commercial costs or activities not captured within the
 251 HES data extraction.

252

253 Table 1: Data Captured in Study

2017_18	Reference Costs	Extracted HES	Captured
Organisation providing returns	152		
Bed-days	26,462,497	25,932,385	98%
Tariff Charged	£26,219,369,965	£19,392,269,892	74%
Outpatient Attendance	87,714,235	119,758,272	137%
A&E Attendances	19,950,458	20,737,416	104%

254

255 The NDA Register showed that out of a total population of 56 million in England, 2.9
 256 million (6.5%) had T2DM and 270 thousand (0.7%) had T1DM. The bed day analysis
 257 confirmed that 17% of beds were occupied by T2DM and 3% by T1DM at a total of
 258 20% on average of bed occupancy similar to that reported in the National Inpatient
 259 Audit (2).

260

261 The National average reference 2017_18 costs for a both consultant and non-
 262 consultant led outpatient appointment is £125/attendance. The national average
 263 reference costs for an A&E attendance including all the activities were
 264 £160/attendance.

265

266 Table 2 Scope of Study

2017_18	Practices		Population	NDA T2		NDA T1	
Total	7,255		59,005,024		2,914,825		243,090
Complete Data	6,676		55,924,632		2,835,540		236,025
T2>200	5,468	75%	51,352,503	87%	2,656,850	91%	

267

268 Included into the study (Table 2) were practices for which there was enough data
 269 and for this we only included practices with more than 200 T2DM patients with
 270 respect to the estimation of age impact.

271

1
2
3 272 The results of the expected prevalence calculation are shown in Figure 1. GP
4 273 practices with a higher proportion of black and minority ethnicity (BME) ethnicity
5 274 individuals, people with hypertension and coronary artery disease plus an older age
6 275 profile had higher proportions of T2DM individuals. The statistical model based on
7 276 these factors accounted for 74% of the variation in T2DM prevalence across GP
8 277 practices in England. Higher proportion of black and minority ethnicity individuals, of
9 278 those with a history of hypertension, higher proportion on the coronary artery disease
10 279 register and higher proportion aged 65 or more were the strongest predictors of
11 280 higher T2D prevalence. A "T2 Case Identification" for each practice was then taken
12 281 as the actual prevalence of T2 divided by the expected value.
13
14
15
16
17
18
19
20
21

22 283 Figure 2A shows the age profile (proportion at a particular age) of non-diabetes,
23 284 T1DM and T2DM in the England general population. For T2DM the age distribution
24 285 is considerably different from the non-diabetes population, while the T1DM age
25 286 distribution is close to the non-diabetes population. The figure also shows the
26 287 proportion over 65 within each of these diagnostic categories (T1DM, T2DM and
27 288 non-diabetes) for hospital attendees. For hospital attendees the proportion of
28 289 admissions in the over 65 age for T2DM at 66% was much higher than for non-
29 290 diabetes individuals at 22% and T1DM at 15%.
30
31
32
33
34
35
36
37

38 292 The age profile data showed that across all GP practices in England, for non-
39 293 diabetes 7% of people were aged >75 years and for people with T2DM 26% were
40 294 aged >75 years old.
41
42
43
44

45 296 Figure 2B shows the variation of total hospital costs by proportion of people on the
46 297 GP list >75 years old. The univariate linear regression based on GP practice level
47 298 total costs of hospital activity versus age profile of the practice, shows that if 7% of
48 299 people were aged >75 years in the GP practice, that the expected total non-diabetes
49 300 population costs would be expected to be £568/person. However if the figure was
50 301 26% of people aged >75 years then the equivalent non-diabetes population costs
51 302 would rise to £884/person. This univariate analysis suggests that the increased age
52 303 of T2DM people accounts for up to £316/person of the cost difference.
53
54
55
56
57
58
59
60

305 Multivariate Regression Analysis for T2DM hospital costs

1
2
3 306 Figure 3A-3E shows the results from 5 of the multivariate regression models used to
4 link the level of cost and activity / T2DM person to the main drivers from the practice
5 307 and levels for the non-diabetes populations including age of both non-diabetes and
6 308 T2DM %>75.
7
8 309
9

10 310

11 The variation captured in each model was between 0.26 and 0.63. The regression
12 311 analysis shows that the main driver for T2DM diabetes service costs and activity are:
13 312

- 14 313 • Equivalent service costs for the non-diabetes population
- 15 314 • Age %>75 of the T2DM population

16 315 For the factors associated with lower T2DM hospital costs:

- 17 316 • Prevalence %T2DM
- 18 317 • Age%>75 of the non-diabetes population
- 19 318 • T2DM% case identification

20 319 Minor Factors that had variable effects included:

- 21 320 • Social Deprivation
- 22 321 • Practice Size
- 23 322 • T2DM Prevalence
- 24 323 • %BME ethnicity
- 25 324 • Northerly latitude.
- 26 325 • Population Density (urban/rural)

27 326

28 327 Similar patterns were seen across hospital total costs, non-elective costs, elective
29 328 costs, outpatient total attendances and A/E total attendances.
30 329

31 330 To extrapolate the level of the age effect contained within the T2DM activity and
32 331 costs, the multiple regression coefficient for the proportion of T2DM individuals aged
33 332 >75 years was taken for each measure from the analysis and applied to the
34 333 difference between the T2DM value of 26% >75 years vs 7% of the non-diabetes
35 334 population>75 years old. The age-related impact on T2DM total acute costs
36 335 difference/person are £300/person. This was similar to the £316 calculated by the
37 336 univariant analysis.
38 337

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 338 Figure 4 highlights the relation of the diagnosis of T1DM and T2DM with percentage
4
5 339 of total hospital activity. While the numbers of T1DM are 0.42% and T2DM are
6
7 340 5.06% of the total background population, having allowed for the normal needs and
8
9 341 influence of age, the net diabetes impact as a condition is 8.5% of hospital costs of
10
11 342 the NHS (T1DM 1.8% +T2DM 6.7%). In making up this net total 13.9% are for
12
13 343 emergency costs (T1DM 2.9% + T2DM 11%), 9.2% are for elective costs (1.4%
14
15 344 T1DM + 7.8% T2DM), 6% are for outpatient attendances (1.6%T1DM + 4.4%T2DM)
16
17 345 and 2.2% are for A&E attendances (0.9% T1DM and 1.3% T2DM). Overall diabetes
18
19 346 patients are taking 19.3% of bed days, but after allowing for normal needs and age
20
21 347 related, then the additional consumption is 11.9% of emergency beds (2.8%T1DM +
22
23 348 9.1%T2DM) and 5.4% elective beds (1.5%T1DM + 3.9%T2DM).

24
25 350 Table 3 provides an overview of the costs of diabetes including the impact of age on
26
27 351 T2DM. £35.6 billion/year of hospital spend are included in this analysis. This
28
29 352 accounts for 66% of £53.7billion total hospital income in England in 2017/18 with the
30
31 353 overall cost of hospital care for people with diabetes being £5.6 billion/year. Once the
32
33 354 normal expected costs including the older age of T2DM hospital attenders are
34
35 355 allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care
36
37 356 costs. Of this £0.65 billion or 21% of the age adjusted diabetes spend came from the
38
39 357 additional treatment provided to T1DM individuals who were only 8% of the total
40
41 358 diabetes population. This equates to £560/non-diabetes person compared to
42
43 359 £3,280/person with T1DM and £1,686/person with T2DM (of this £300 is associated
44
45 360 with the age difference so the net impact on hospital costs is £826/person).

46
47 361
48 362 T1DM individuals required 5.9 x as much secondary care activity as non-diabetes
49
50 363 individuals. For T2DM, having allowed for the age difference there is 2.5 x secondary
51
52 364 care activity as non-diabetes individuals. The main area for these costs difference
53
54 365 was emergency / non elective care with 9.6 x the non-diabetes level for T1DM and
55
56 366 3.7 x non diabetes level for T2DM. The elective treatment costs were 4.7 x for T1DM
57
58 367 and 2.8x higher for T2DM than for non-diabetes.
59
60 368

Table 3: Results The numbers and activities associated with 6,791 GP practices that had provided both HES activity and NDA data.

	TOTAL	Non-Diabetes	T1DM	T2DM	T2 Age Adjust	Net T1DM ⁴	Net T2DM incl Age	DM Imp ⁵ % Total	T1 as % DM	Multiple of Non-Diabetes Unit	
										T1	T2 Age Adjusted
Population ,000	56,915	53,796	239	2,880							
Hospital Spend (£million):											
Non Elective Tarif	£8,859	£6,756	£288	£1,815	£-479	£258	£975	14%	21%	9.6	3.7
Elective Tarif	£9,270	£7,809	£164	£1,297	£-140	£129	£739	9%	15%	4.7	2.8
Outpatient (@£125each)	£14,305	£12,503	£291	£1,511	£-210	£235	£632	6%	27%	5.2	1.9
A&E (@£160each)	£3,159	£2,885	£42	£232	£-35	£29	£42	2%	41%	3.2	1.3
TOTAL	£35,593	£29,953	£784	£4,855	£-864	£651	£2,388	9%	21%	5.9	2.5
Admissions & Bed days: ,000											
Non Elective Bed-days	14,204	10,980	445	2,779	-892	396	1,299	12%	23%	9.1	3.2
Non-Elective Adm ¹	5,853	4,742	163	948	-246	142	448	10%	24%	7.7	2.8
Elective Bed-days	10,462	8,924	194	1,345	-457	154	409	5%	27%	4.9	1.9
Elective Adm ON ²	4,774	3,949	191	635	17	173	441	13%	28%	10.9	3.1
Elective Adm DC ³	6,799	5,858	74	866	-37	48	515	8%	9%	2.9	2.6
Length of Stay Days (LOS):										% of Non D	
Non-Elective LOS	2.43	2.32	2.72	2.93		2.72	2.69			118%	116%
Elective LOS	2.19	2.26	1.01	2.12		1.01	1.36			-55%	-40%
Attendances: ,000											
Outpatient	114,439	100,024	2,324	12,091	-1,682	1,879	5,054	6%	27%	4.8	1.9
A&E	19,742	18,034	260	1,448	-219	180	264	2%	41%	3.1	1.3

¹Adm = Admissions ²ON= Overnight ³DC= Daycase ⁴Net = Total after taking away non-diabetes costs and age factor ⁵Imp=Impact of additional resources for DM

Total Inpatient Tariff Charges

The total admission tariff charges for people with diabetes is £3.5 billion/year. £2.1 billion is for non-elective/emergency and £1.4 billion elective work. Of this £0.9 billion would be chargeable for average non-diabetes activity plus £0.6 billion can be associated with the older age of the T2DM. Therefore the total net additional costs are £2 billion/year - this splits as £0.4 billion T1DM (£1,620/person) and £1.6 billion T2DM (£595/person).

For the non-diabetes population non-elective/emergency tariff charges are 46% of the total admission charges. For people with diabetes the net excess impact on non-elective/emergency work is £1.2 billion or 60% of the total net excess; this splits as £3,090/person T1DM and net £340/person/T2DM.

Bed Occupancy

The recorded 24.7 million bed days is equivalent to 67,577 fully occupied beds; of these 13,047 or 19.3% were taken by people with either T1DM or T2DM. 6,858 beds occupied (10%) can be explained by the expected health requirements of older age people. The remaining 6,183 (9.1% of total) can be considered a direct consequence of the additional comorbidities associated with diabetes. Of these 1,645 (26% of DM excess total) excess beds are occupied by T1DM.

Closer examination of beds occupied by patients admitted in non-elective/emergency circumstances revealed that out of the total 38,914 fully occupied beds 8,832 (22.6%) were occupied by people with diabetes, and allowing for the expected 4,576 normal and older age, the excess in emergency is 4,256 beds - these are 11% of the total non-elective beds and 68% of the overall excess diabetes beds. It is also worth noting that 1,174 of the excess non-elective beds are taken by T1DM people, making up 70% of the total 1,645 T1DM excess beds.

Length of Stay (LOS) – excluding day cases

An average length of stay for both elective overnight and emergency admissions can be calculated by dividing their total bed-days for both T1DM and T2DM (age

1
2
3 adjusted) by their total number of overnight admissions for T1DM and T2DM (age
4 adjusted). These values can then be compared to the two different LOSs for the non-
5 diabetes population.
6
7

8
9
10 The non-elective LOS for both T1DM and T2DM are only around 10% longer than
11 non-diabetes, so most of the higher non-elective or emergency bed occupancy in
12 diabetes must come from an increased rate of admission rather than LOS.
13
14

15
16
17 The elective LOS data are intriguing with overnight elective length of stay for T1DM
18 is at 1.0 day/person around 50% of the non-diabetes. For T2DM at 1.46 days/person
19 LOS is 62% of the non-diabetes LOS. This suggests that these patients are receiving
20 higher numbers of planned short overnight admissions across a number of
21 specialities, to treat some of the consequences of their condition.
22
23
24

25 26 27 28 Elective Daycase

29 The evidence shows that elective daycase admissions for both T2DM (age adjusted)
30 and T1DM are around 2.5 times the level of the non-diabetes patients. This will
31 include day case podiatry procedures, ophthalmology and dialysis day case
32 attendances. This suggests that the increase in diabetes associated comorbidities
33 does also increase the amount of elective treatments levels that people with diabetes
34 require.
35
36
37
38
39

40 41 42 Outpatient Attendances

43 There was a big difference between the additional number of outpatient attendances
44 that a person with T1DM patients showed with 4.8 times the non-diabetes
45 attendances compared to the 1.8 times for T2DM. This might be due to the larger
46 number of ongoing checks are being given to people with T1DM for eye, foot and
47 renal complication management. The total additional outpatient attendances
48 provided to people with diabetes to cover all the consequences of their condition was
49 estimated at 6.9 million or 6% of all outpatient attendances. At an estimated average
50 reference cost of £125/attendance this costs the NHS total £825 million/year.
51
52
53
54
55
56
57
58
59
60

A&E Attendances

A&E attendances for T1DM were 3.1 times higher and T2DM 1.3 times higher than non-diabetes. The total additional estimated diabetes related A&E attendances at 440 thousand was 2% of all the A&E attendances in England in 2017/18. At an average cost of £160/attendance this costs the NHS a total of £70 million/year.

Discussion

There has been much discussion about the true cost of diabetes to the NHS. There is already significant investment in managing the 3.2 million people identified with diabetes. The spend on glycaemic control medication alone in 2017_18 was over £1 billion. This analysis shows that additional costs of provision of hospital services due to their diabetes comorbidities is £3 billion above those for non-diabetes and that within this T1DM have three time as much cost impact as T2DM. We have not included other forms of diabetes such as maturity onset diabetes of the young (MODY) or secondary diabetes in our analysis, as the numbers of people with these conditions are likely to be quite low at individual GP practices and coding of diagnosis is likely variable in accuracy.

Hex et al (2012) (8) in “Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs” estimated the total secondary care costs at £7.7billion with excess in-patient days at a cost £1.8 billion of which 99% was on T2DM. Marion Kerr in ‘Inpatient Care for People with Diabetes: The Economic Case for Change for Insight Health Economics’ November 2011 (9) estimated the additional impact at £573 million – £686 million. Neither of these previous analyses took account of the age distribution difference between T2DM individuals and the non-diabetes population as we have done here.

Hex et al. (8) also indicated that less than 25% of that diabetes treatment cost relates to the costs of management of diabetes, with the rest being accounted for by the costs of treating the complications of diabetes, which in one sense could be seen

1
2
3 as 'adverse events'. Another factor highlighted in this paper is that the indirect costs
4 of diabetes are considerably higher than the direct costs and many relate to a cost to
5 the individual with diabetes or to their carers. Cost estimates for productivity and
6 social costs are often opportunity costs, such as time lost that could be spent on
7 other activities (9). Furthermore one quarter of care home residents in the UK have
8 T2DM (10). Access issues, where there are frailty and mobility problems preventing
9 routine GP or hospital appointment visits can result in services being quite variable in
10 delivery from one area to another (11).
11
12
13
14
15
16
17

18
19 An International Diabetes Federation study (12) showed that people with diabetes
20 have medical costs that are two to three times more than age and sex matched
21 patients without diabetes ie that if the average healthcare cost per person without
22 diabetes is \$1,000 (£787), while for a similar person with diabetes the cost will be
23 \$2,000-\$3,000. These figures are not dissimilar to those reported in our study - of
24 £560/non-diabetes person compared to £1,810/person with diabetes. The significant
25 excess of non-elective and elective activity and costs for T1DM individuals is
26 indicative of the complexities of management of this condition and is related to the
27 fact that many people with T1DM do not achieve target glycaemic control with
28 hypoglycaemia, a frequent cause of Hospital A/E attendance (13).
29
30
31
32
33
34
35
36
37

38 There is also large pressure on hospital beds and especially with emergency
39 admissions. That 11% of emergency beds are occupied by patients being admitted
40 through the direct consequences their diabetes and 27% of these are T1DM, shows
41 that supporting patients in managing their diabetes remains a clear focus for primary
42 care with T1DM remaining a very important aspect. Length of stay as reported here
43 is also a factor and this can be impacted on significantly by effective deployment of
44 diabetes specialist nurses on wards (14).
45
46
47
48
49
50

51 The total additional outpatient attendances provided to people with diabetes to cover
52 all the consequences of their condition was estimated at 6.9 million or 6% of all
53 outpatient attendances. This might be due to the larger number of ongoing checks
54 that are being given to people with T1DM for eye, foot and renal complication
55 management and to many people with T1DM. This also highlights a possible
56
57
58
59
60

1
2
3 opportunity to deliver more of these services in the community rather than in the
4 hospital for these patients.
5
6
7

8 The higher number of elective daycase, elective and A/E attendances likely are a
9 consequence of management of diabetes complications and comorbidities in both
10 T1DM and T2DM.
11
12
13

14
15 We know that people with diabetes are constantly managing their condition on a
16 daily basis but may only come into contact with healthcare professionals a couple of
17 times a year. Therefore education programmes that give people the knowledge and
18 motivation to manage their condition are essential. For people with T1DM, Dose
19 Adjustment Normal Eating (DAFNE) (15) is an education course that trains people to
20 estimate the carbohydrate in each meal and to inject the right dose of insulin. A cost-
21 effectiveness analysis (16) based on economic data from randomised control trials
22 on DAFNE and similar programmes in Germany and Austria shows very good
23 results. A seven year follow-up on UK patients who went on a DAFNE course
24 showed that their glycaemic control remained better than a similar group who had
25 not been on the course (17). Over 10 years, structured treatment and teaching
26 programmes save £2,200 per patient. The majority of the savings arose from
27 avoiding dialysis and foot ulceration.
28
29
30
31
32
33
34
35
36
37
38

39 Education for people with T2DM is also cost effective. Data from a leading education
40 programme, X-PERT, shows the costs are outweighed by savings in cardiovascular
41 and diabetes medication (18). A systematic review rated X-PERT as very cost-
42 effective (19). Another major education programme, Diabetes Education and Self
43 Management for Ongoing and Newly Diagnosed (DESMOND) (20), is also effective
44 with the key benefits being reductions in weight and smoking rate (21).
45
46
47
48
49
50

51 In our recent papers (6,7) we showed that access to expert patient programmes can
52 result in significant improvements in glycaemia control as can informed choice of
53 diabetes medication. If achieved, such improvements in glycaemia have the potential
54 to reduce hospital costs in the longer term.
55
56
57
58
59
60

1
2
3 Healthcare systems influence a broad range of treatment decisions, both directly, via
4 implemented policies/guidelines, and indirectly through impact of short duration of
5 clinical appointments and patients' perceptions of their healthcare needs. We hope
6 that this paper will be helpful to those in who direct policy in healthcare both in the
7 UK and elsewhere in the world.
8
9
10
11
12
13

14 **Conclusion**

15
16 People with diabetes have a significant impact on hospital activity. They are admitted
17 more often especially as emergencies and stay on average for longer. People with
18 T1DM, although 10% of the people with diabetes have more than threefold the
19 impact of T2DM, so require more special attention. However people with T2DM have
20 wider range of comorbidities and so can be more complex.
21
22
23
24
25

26 Improved management of T1DM and T2DM in primary care can reduce the level of
27 hospital activity and hospital costs. The role of the secondary care specialist team in
28 supporting primary care and ensuring that most people with diabetes are being well
29 managed not just focussing on the smaller in number hardest to treat group, will be a
30 key factor in improving primary care management outcomes. This could potentially
31 reduce the excess hospital activity and attendant costs consequent on managing the
32 longer term consequences of all forms of diabetes.
33
34
35
36
37
38
39

40 **Figure legends:**

41
42 Figure 1: T2DM Identification. T2DM Identification. Statistical model linking % of
43 T2DM to a number of practice factors. Factors contributing related to higher T2DM
44 prevalence are on the right of the figure.

45
46 Figure 2A: Age Distribution (proportion at a particular age) in the general population
47 by diabetes type and proportion aged >65 years in hospital patients. Figure 2B:
48 Impact in practices non-diabetes population of Age% > 75 years old on total hospital
49 costs/non diabetes population
50

51 Figure 3: Figure 3A-3E shows the results from 5 multivariate regression models
52 linking to selected practice factors for T2DM related hospital activity
53

54 Figure 4: Comparison of hospital activity between non-diabetes and T1DM (split by
55 impact of population and condition) and T2DM (split by impact population, age and
56 condition)
57
58
59
60

References

1. WHO Global Report on Diabetes 2016. Accessed at <https://apps.who.int/iris/>: Accessed on 31 May 2019
2. National Diabetes Inpatient Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit/>: Accessed 25 May 2019
3. NHS Digital HES data at <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>: Accessed 21 May 2019
4. National Diabetes Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit/>: Accessed 25 May 2019
5. *HERC (2018) Yorkshire and the Humber Public Health Observatory Data* https://www.herc.ox.ac.uk/health_datasets/...data.../yorkshire-and-the-humber-public-health-observatory-indicator-search-tool: Accessed 26 May 2019
6. Heald AH, Livingston M, Malipatil N, Becher M, Craig J., Stedman M, Fryer A, Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit. *Diabetes Obes Metab* 2017; 20: 185-194
7. Heald AH, Livingston M, Fryer A, Moreno GYC, Malipatil N, Gadsby R, Ollier W, Lunt M, Stedman M, Young RJ. Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit. *Diabet Med* 2018; 35: 63-71
8. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs York Health Economics Consortium Ltd, University of York, *Diabetic medicine* 2012; 29: 855-62
9. Inpatient Care for People with Diabetes: The Economic Case for Change Marion Kerr Insight Health Economics, at https://www.diabetes.org.uk/resources-s3/2017-1_1.pdf: Accessed 14 June 2019
10. www.kingsfund.org.uk/sites/default/files/field/field_document/managing-people-long-term-conditions-gp-inquiry-research-paper-mar11.pdf: Accessed 23 May 2019
11. Good clinical practice guidelines for care home residents with diabetes. (January 2010). Available at: http://www.diabetes.org.uk/About_us/Position-statements--recommendations/Care-recommendations/Good-clinical-practice-guidelines-for-care-home-residents-with-diabetes: Accessed 25 May 2019
12. Zhang et al. Economic impact of diabetes in Diabetes Atlas fourth edition. International Diabetes Federation: Brussels. 2009. http://www.idf.org/sites/default/files/Economic_impact_of_Diabetes.pdf: Accessed 26 May 2019
13. Wang H, Donnan PT, Leese CJ, Duncan E, Fitzpatrick D, Frier BM, Leese GP. Temporal changes in frequency of severe hypoglycemia treated by emergency medical services in types 1 and 2 diabetes: a population-based data-linkage cohort study. *Clin Diabetes Endocrinol* 2017; 3: 7
14. <https://diabetestimes.co.uk/diabetes-nurses-group-celebrates-anniversary-2/>: Accessed 23 June 2019

15. Lawton J, Rankin D, Cooke D, Elliott J, Amiel S, Heller S. UK NIHR DAFNE Study Group. Patients' experiences of adjusting insulin doses when implementing flexible intensive insulin therapy: a longitudinal, qualitative investigation. *Diabetes Res Clin Pract.* 2012 98: 236-42
16. Shearer et al. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. *Diabetic Medicine* 2004; 21: 460-7
17. Gunn, D, Mansell, P. Glycaemic control and weight seven years after DAFNE structured education in Type 1 diabetes. *Diabetic Medicine* 2012; 29: 807-12
18. Deakin, T. The diabetes pandemic: is structured education the solution or an unnecessary expense? *Practical Diabetes* 2011, 28 NO. 8. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/pdi.1635>: Accessed 29 May 2019
19. Jacobs-Van Der Bruggen MAM, et al. Cost-effectiveness of lifestyle modification in diabetic patients. *Diabetes Care* 2009; 32:1453–8.
20. Gillett et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ* (2010)
21. Davies MJ, et al. Effectiveness of the diabetes education for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster ra

Transparency statement

Dr. Heald as corresponding author affirms that this is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics Statement

As we used publicly available and GP level data, with no individual patient data, it was not necessary to seek Ethics Approval for this study.
This was not a clinical trial.

Funding

The relevant HES data was extracted from NHS Digital Hospital Episode Statistics by Wilmington Healthcare and provided by NAPP Pharmaceuticals.

Role of the Sponsor

There was no research sponsor for this study

Dissemination of study results to participants

Dissemination to specific participants will not be possible as all data was anonymised and at GP practice level.

Patient Consent

This was not applicable as we analysed practice level data here.

Data Availability

We used publicly available data for the analysis and findings that we report in this paper.

Duality of interest

No author has anything to disclose in relation to conflict of interest.

Contribution Statement

MS, MD and AHH conceived the study. MS collected the data. MS and ML conducted the data analysis. MS, ML, MD, AF, CD, MG, RG, SGA GR and AHH all contributed to writing of the paper. SGA, GR, RG, AF and MG provided an over view of the manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Regression model results for GP practice level prevalence of T2DM to then be used to calculate denominator in practice case identification %

126x94mm (300 x 300 DPI)




Figure 2A: Age Distribution and %attending hospital age>65 for Non Diabetes, T1DM and T2DM populations
 2B Correlation between GP practice %Age>75 and average overall non diabetes costs/population

108x174mm (300 x 300 DPI)




Figure 3A-E: Regression model for T2DM linking hospital costs / activity to other factors including age

182x179mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4: Splitting total hospital costs and activities between non-diabetes, T1DM and T2DM populations, including for impact of T2DM age difference and DM condition

226x103mm (300 x 300 DPI)

BMJ Open

The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033231.R1
Article Type:	Original research
Date Submitted by the Author:	31-Jan-2020
Complete List of Authors:	Stedman, Mike; Res Consortium Lunt, Mark; University of Manchester, ARC Epidemiology Unit Davies, Mark; Res Consortium Livingston, Mark; Walsall Healthcare NHS Trust, Clinical Biochemistry Duff, Christopher; University Hospitals of North Midlands NHS Trust, Department of Clinical Biochemistry Fryer, Anthony; Keele University, Institute for Science & Technology in Medicine Anderson, Simon; University of the West Indies Cave Hill Campus, The George Alleyne Chronic Disease Research Centre Gadsby, Roger ; University of Warwick Warwick Medical School Gibson, Martin; Salford Royal Hospital, Endocrinology and Diabetes Rayman, Gerry; Ipswich Hospital NHS Trust, The Ipswich Diabetes Centre and Research Unit Heald, Adrian; Leighton Hospital, Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Health economics, Public health, Diabetes and endocrinology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, HEALTH ECONOMICS, PUBLIC HEALTH, Hospital

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2
5 diabetes (T2DM) compared to the non-diabetes population: a detailed
6 economic evaluation
7
8
9
10

11 Mike Stedman¹, Mark Lunt², Mark Davies¹, Mark Livingston³, Christopher J Duff^{4,5},
12 Anthony Fryer^{4,5}, Simon G Anderson², Roger Gadsby⁶, Martin Gibson², Gerry
13 Rayman⁷, Adrian Heald^{1,8}
14
15

16
17
18
19 ¹Res Consortium, Andover, Hampshire; ²The School of Medicine and Manchester
20 Academic Health Sciences Centre, University of Manchester, Manchester;
21 ³Department of Clinical Biochemistry, Black Country Pathology Services, Walsall
22 Manor Hospital, Walsall; ⁴Department of Clinical Biochemistry, University Hospitals of
23 North Midlands NHS Trust, Stoke on Trent; ⁵Institute for Science and Technology in
24 Medicine, Keele University; ⁶Warwick Medical School, University of Warwick,
25 ⁷Department of Diabetes and Endocrinology, Ipswich General Hospital, ⁸Department
26 of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK
27
28
29

30
31
32 Corresponding author: Dr Adrian Heald
33 Department of Diabetes and Endocrinology,
34 Salford Royal Hospital, Salford, UK.
35 M6 8HD
36

37
38 Telephone: +44 161 206 5157
39

40 Email: adrian.heald@manchester.ac.uk
41

42 Manuscript word count (main text): 3998
43
44

45
46
47 Keywords: Type 2 diabetes, Type 1 diabetes, Hospital, HES, Cost, GP practice
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Key messages:
4
5
6

- 7
- We aimed to more exactly quantify the net impact of diabetes on the different aspects of healthcare provision in hospitals in England.
 - The study captured around 90% of the hospital activity and £36 billion/year of hospital spend.
 - Once the normally expected costs including the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care costs. This equates to £560/non-diabetes person compared to £3,280/person with T1DM and £1,686/person with T2DM.
 - There are still opportunities to reduce potential future additional costs further through increased investment in local services and medication for diabetes treatment.
- 20
21
22

23 Article Summary:

24 Strengths and Limitations of the Study

25
26
27 **Strengths of this study**

- 28
- We were able to look at national level data across nearly 5500 GP practices in relation to hospital activity. The analysis covered more than 90% of hospital costs in England.
- 32
33

34 **Limitations of this study**

- 35
- Any conclusions drawn must account for the fact that our findings are based on association, not definite causation.
 - Inherent in this real-world analysis methodology are potential confounding factors that are inherent in any retrospective study. Nevertheless, our design was such as to minimise the potential impact of such factors.
- 44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

Other than age, diabetes is the largest contributor to overall health care costs and reduced life expectancy in Europe. This paper aims to more exactly quantify the net impact of diabetes on different aspects of healthcare provision in hospitals in England, building on previous work that looked at the determinants of outcome in T1DM and T2DM.

Setting

NHS Digital Hospital Episode Statistics (HES) in England was combined with the National Diabetes Audit (NDA) to provide the total number in practice of people with T1DM/T2DM.

Outcome measures

We compared differences between T1DM/T2DM and non-diabetes individuals in relation to hospital activity and associated cost.

Results

The study captured 90% of hospital activity and £36 billion/year of hospital spend. The NDA Register showed that out of a total reported population of 58 million, 2.9 million (6.5%) had T2DM and 240 thousand (0.6%) had T1DM. Bed day analysis showed 17% of beds are occupied by T2DM and 3% by T1DM.

The overall cost of hospital care for people with diabetes is £5.5 billion/year. Once the normally expected costs including the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care costs. This equates to £560/non-diabetes person compared to £3,280/person with T1DM and £1,686/person with T2DM.

For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion with additional estimated diabetes-related A&E attendances at 440,000 costing the NHS £70 million/year.

T1DM individuals required five times more secondary care support than non-diabetes individuals. T2DM individuals, even allowing for the age, require twice as much support as non-diabetes individuals.

Conclusions

There may still be opportunities to reduce potential future additional costs through increased investment in local services and medication for diabetes treatment. Supporting patients in diabetes management may significantly reduce hospital activity including emergency bed occupancy of people with T1DM/T2DM.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Other than age, diabetes is the largest contributor to overall health care costs and reduced life expectancy in Europe (1). People with Type 1 (T1DM) and Type 2 (T2DM) diabetes require much higher levels of hospital support than their non-diabetes counterparts. Health care provision in hospital can be broken down into four main areas: 1) planned/elective including day-case admissions (Planned), 2) emergency/non-elective admissions (Emergency), 3) accident & emergency (A&E) attendances and 4) outpatient consultations/attendances (Outpatient). Each of these different classes must be managed appropriately by clinicians and hospital administrators and the relevance of diabetes to this planning may be different.

The National Diabetes Inpatient Audit (2) has shown that 18% of all hospital beds on any one day are occupied by people who have a diagnosis of diabetes (2) compared to a 7% prevalence of all diabetes in the adult population of England. This may significantly overstate the impact of the condition as over 90% of people with diabetes have T2DM, which generally occurs much later in life so that the cohort is significantly older than the general population – as such their normal healthcare requirements would increase significantly with age.

NHS Digital publishes the general practitioner (GP) practice patient register split into age groups and can provide practice level extracts from hospital episode statistics (HES) of the amount of different practice activities for people who have a recorded diagnosis of T1DM or T2DM and those that do not have such a diagnosis (3). The National Diabetes Audit publish the numbers and ages of people with either T1DM or T2DM in each practice (4) also split into age groups. Other practice characteristics such as ethnicity, social deprivation, location, are also publicly available (5).

The NHS in England publishes a significant amount of data at a GP practice level and we have previously described the impact of a variety of population, service and prescribing factors on outcomes (6,7). We have previously looked at the determinants of outcome in T1DM and T2DM in GP practices in England (6,7). It was felt that this approach could be used to quantify and so adjust for the effect of age on different services that are provided in hospital to T2DM individuals and therefore achieve a much more accurate evaluation of the actual net cost of diabetes, including all associated comorbidities to the health service.

Aims

This paper aims to more exactly quantify the net impact of diabetes on the different aspects of healthcare provision in hospitals in England.

At GP practice level, we took the allocation of the different elements of hospital costs associated with the diagnosis of either T2DM or T1DM while adjusting for the difference in the T2DM age profile from the general population. We wished to use this analysis to provide a clearer focus for diabetes services to determine which elements of care they can focus on, in order to improve outcomes. Specifically, we compared differences between T1DM/T2DM and non-diabetes individuals in relation to hospital activity and the associated costs.

Methods

Individual patients who had a diagnosis of either T1DM or T2DM and their age and practice code were identified within the NHS Digital Hospital Episode Statistics (HES) data for 2016_17 and 2017_18. The sum of annual activity of the different services, including emergency, elective, A&E and outpatient care, was then extracted from the NHS Digital HES for each general practice for all those patients with a diagnosis of T1DM or T2DM and the non-diabetes individuals in 2017_18. Emergency and elective activity were shown as totals for the number of unique patients, admissions, overall bed-days, and the total national tariff charged, while only the number of unique patients and total attendances were provided for outpatient and A&E activity. The completeness of data was checked by looking at the national totals for the year reported within the reference costs.

The actual total population of T1DM and T2DM individuals and their age groups at the GP practice level was taken from NHS Digital National Diabetes Audit (4). Public Health England publishes the patient numbers and age profile of each GP practice from this total. The age profile for non-diabetes patients was calculated by subtracting the total diabetes population.

The demographic and locational data for each practice including social deprivation, population density (urban/rural), Latitude (Northerliness) were taken from the Office of National Statistics (ONS) (5). The % minority ethnicity was also determined.

1
2
3
4
5 The total overall hospital costs for each practice in each of the three classes (T1DM, T2DM,
6 and non-diabetes) were calculated by adding the provided total elective & non-elective tariff
7 charges to the Outpatient and Accident & Emergency attendances each multiplied by the
8 national overall average cost/attendance taken from the 2017-18 national reference costs.
9
10
11
12
13

14 For each of the T1DM, T2DM and Non-diabetes population: Total Hospital Costs = Total
15 recorded Elective Tariff Charges + Total recorded Non-Elective Tariff Charges+ Total recorded
16 Outpatient Attendances x Average annual Outpatient tariff cost/attendance + Total recorded
17 Accident & Emergency attendances x average cost / attendance (both taken from the 2017-
18 18 national reference costs).
19
20
21
22
23

24 The number of practices included in the study was limited to those for which all the data sets
25 were available plus if there were more than 200 T2DM patients or more than 20 T1DM patients
26 on their register (5468 GP practices).
27
28
29
30
31
32

33 Practices that identify people earlier in the course of their T2DM increase their numbers and
34 pro-rata this reduces the associated average hospital costs/person, to include for this a “T2DM
35 %case identification” factor was calculated. Our statistical model took account of this and
36 linked the actual recorded T2DM register as % of the total practice population to the practice
37 age, gender, ethnicity, social disadvantage, latitude, and main long-term condition disease
38 prevalence. Based on this statistical model an expected level of T2DM could be predicted.
39 The difference between the predicted and actual T2DM prevalence was taken as the local
40 practice % case identification. This factor was not required for T1DM as the onset of that
41 condition is more clearly delineated, so all people with this condition can be more easily
42 identified.
43
44
45
46
47
48
49
50
51

52 Patient and Public Involvement Statement

53 It was not appropriate or possible to involve patients or the public in this work given that we
54 used general practice level summated data and related hospital outcome statistics.
55
56
57
58
59
60

Statistics

A stepwise multiple regression model was created using Excel with Analyse-it add-in linking as outcome level of hospital activity of each class/head of population for T1DM and T2DM at GP practice level to the:

- The same measure for the non-diabetes population
- % of non-diabetes population age >75
- % of either T1DM or T2DM
- % case Identification (T2DM)
- Population Density (pop/sq km)
- % Black and Minority Ethnicity (BME)
- Practice Size
- % Prevalence of T2DM
- Latitude

To remove the effect of the age difference between T2DM and non-diabetes population on the cost impact of diabetes, the regression coefficient was applied to the difference between % on patients over 75 in T2DM and the non-diabetes population, to give a “net” T2DM disease impact on each of the activities and cost levels including:

- Overall Costs
- Emergency Admissions, Bed days & Tariff
- Elective Admissions, Day case, Bed days & Tariff
- A&E Attendances
- Outpatient Attendances

To highlight the impact of the condition he activity/person for T1DM and T2DM was also shown as a ratio to the non-diabetes activity/person.

As diabetes can have many wide-ranging health impacts establishing the overall additional all-cause hospital costs of diabetes on top of expected normal healthcare needs is difficult. Using a practice population based approach allows us to allow for confounding factors such as age and disease identification. However, it remains a statistical analysis relying on large amounts of data entered during clinical treatments so it will contain normal administrative errors. Nevertheless, it is hoped that both the scale of this data capturing over 160 million

episodes and as these errors can be either over or under reported that the outcomes should correspond to the actual values.

Results

The study (See Table 1) captured around 90% of the hospital activity data for England in 2017/18. The missing 10% could be explained by the difference in definitions between the different analyses (i.e. outpatient attendances and episodes which include more than one attendance). The tariff difference between the reference known costs of hospital T1DM/T2DM management and extracted HES of just under £7billion could relate to other commercial costs or activities not captured within the HES data extraction.

Table 1: Data Captured in Study

2017_18	Reference Costs	Extracted HES	Capture d
Organisation providing returns	152		
Bed-days	26,462,497	25,932,385	98%
Tariff Charged	£26,219,369,965	£19,392,269,892	74%
Outpatient Attendance	87,714,235	119,758,272	137%
A&E Attendances	19,950,458	20,737,416	104%

The NDA Register showed that out of a total population of 56 million in England, 2.9 million (6.5%) had T2DM and 270 thousand (0.7%) had T1DM. The bed day analysis confirmed that 17% of beds were occupied by T2DM and 3% by T1DM at a total of 20% on average of bed occupancy similar to that reported in the National Inpatient Audit (2).

The National average reference 2017_18 costs/event for both consultant and non-consultant led outpatient appointments is £125/attendance (8). The national average reference costs for the variety of A&E attendances including all the activities were £160/attendance (8).

Table 2 Scope of Study

2017_18	Practices		Population	NDA T2		NDA T1	
Total	7,255		59,005,024		2,914,825		243,090
Complete Data	6,676	92%	55,924,632	95%	2,835,540	97%	236,025
T2>200	5,468	75%	51,352,503	87%	2,656,850	91%	

1
2
3 Included into the study (Table 2) were practices for which there was enough data and to reduce
4 the impact of single handed practice outliers and decrease the variance only practices with
5 more than 200 T2DM patients were included in the estimation of age impact. This removed
6 18% of practices and 6% of the T2DM population.
7
8
9

10
11
12 The results of the expected prevalence calculation are shown in Figure 1. GP practices with a
13 higher proportion of black and minority ethnicity (BME) ethnicity individuals, people with
14 hypertension and coronary artery disease plus an older age profile had higher proportions of
15 T2DM individuals. The statistical model based on these factors accounted for 74% of the
16 variation in T2DM prevalence across GP practices in England. Higher proportions of black and
17 minority ethnicity individuals, individuals with a history of hypertension, coronary artery
18 disease and aged 65 or over have the strongest association with higher T2D prevalence. A
19 "T2DM Case Identification" for each practice was then calculated from the actual prevalence
20 of T2 divided by the expected value.
21
22
23
24
25
26
27
28
29

30
31 Figure 2A shows the age profile (proportion at a particular age) of non-diabetes, T1DM, and
32 T2DM in the England general population. For T2DM the age distribution is considerably
33 different from the non-diabetes population, while the T1DM age distribution is close to the non-
34 diabetes population. The figure also shows the proportion of over 65 within each of these
35 diagnostic categories (T1DM, T2DM, and non-diabetes) for hospital attendees. For hospital
36 attendees, the proportion of admissions in the over 65 age for T2DM at 66% was much higher
37 than for non-diabetes individuals at 22% and T1DM at 15%.
38
39
40
41
42
43

44 The age profile data showed that across all GP practices in England, for non-diabetes 7% of
45 people were aged >75 years and for people with T2DM 26% were aged >75 years old.
46
47
48
49

50
51 Figure 2B shows the variation of total hospital costs by the proportion of people on the GP list
52 >75 years old. The univariate linear regression based on GP practice level total costs of
53 hospital activity versus age profile of the practice shows that if 7% of people were aged >75
54 years in the GP practice, that the expected total non-diabetes population costs would be
55 expected to be £568/person. However, if the figure was 26% of people aged >75 years then
56 the equivalent non-diabetes population costs would rise to £884/person. This univariate
57 analysis suggests that the increased age of T2DM people accounts for up to £316/person of
58 the cost difference.
59
60

Multivariate Regression Analysis for T2DM hospital costs

Figure 3A-3E shows the results from 5 of the multivariate regression models used to link the level of cost and activity / T2DM person to the main drivers from the practice and levels for the non-diabetes populations including the age of both non-diabetes and T2DM %>75.

Overall hospital costs / various practice populations were normal distributed with skew and kurtosis factors for non-DM = 0.06 & 1.7; T2DM = 0.8 & 2.2 and T1DM = 1.6 & 2.7, mostly within the +/- 2 acceptable range

The variation captured in each model was between 0.26 and 0.63. The regression analysis shows that the main driver for T2DM diabetes service costs and activity are:

- Equivalent service costs for the non-diabetes population
- Age %>75 of the T2DM population

For the factors associated with lower T2DM hospital costs:

- Prevalence %T2DM
- Age%>75 of the non-diabetes population
- T2DM% case identification

Minor Factors that had variable effects included:

- Social Deprivation
- Practice Size
- T2DM Prevalence
- %BME ethnicity
- Northerly latitude.
- Population Density (urban/rural)

Similar patterns were seen across hospital total costs, non-elective costs, elective costs, outpatient total attendances, and A/E total attendances.

To extrapolate the level of the age effect contained within the T2DM activity and costs, the multiple regression coefficient for the proportion of T2DM individuals aged >75 years was taken for each measure from the analysis and applied to the difference between the T2DM value of 26% >75 years vs 7% of the non-diabetes population >75 years old. The age-related

1
2
3 impact on T2DM total acute costs difference/person is £300/person. This was similar to the
4 £316 calculated by the univariant analysis.
5
6
7
8

9
10 Figure 4 highlights the relation of the diagnosis of T1DM and T2DM with the percentage of
11 total hospital activity. While the numbers of T1DM are 0.42% and T2DM are 5.06% of the total
12 background population, having allowed for the normal needs and influence of age, the net
13 diabetes impact as a condition is 8.5% of hospital costs of the NHS (T1DM 1.8% +T2DM
14 6.7%). In making up this net total 13.9% are for emergency costs (T1DM 2.9% + T2DM 11%),
15 9.2% are for elective costs (1.4% T1DM + 7.8% T2DM), 6% are for outpatient attendances
16 (1.6%T1DM + 4.4%T2DM) and 2.2% are for A&E attendances (0.9% T1DM and 1.3% T2DM).
17 Overall diabetes patients are taking 19.3% of bed days, but after allowing for normal needs
18 and age-related, then the additional consumption is 11.9% of emergency beds (2.8%T1DM +
19 9.1%T2DM) and 5.4% elective beds (1.5%T1DM + 3.9%T2DM).
20
21
22
23
24
25
26
27

28 Table 3 provides an overview of the costs of diabetes including the impact of age on T2DM.
29 £35.6 billion/year of hospital spending is included in this analysis. This accounts for 66% of
30 £53.7billion total hospital income in England in 2017/18 with the overall cost of hospital care
31 for people with diabetes being £5.6 billion/year. Once the normally expected costs including
32 the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of
33 the total captured secondary care costs. Of this £0.65 billion or 21% of the age-adjusted
34 diabetes spend came from the additional treatment provided to T1DM individuals who were
35 only 8% of the total diabetes population. This equates to £560/non-diabetes person compared
36 to £3,280/person with T1DM and £1,686/person with T2DM (of this £300 is associated with
37 the age difference so the net impact on hospital costs is £826/person).
38
39
40
41
42
43
44
45
46

47 T1DM individuals required 5.9 x as much secondary care activity as non-diabetes individuals.
48 For T2DM, having allowed for the age difference there is 2.5 x secondary care activity as non-
49 diabetes individuals. The main area for these costs difference was the emergency / non-
50 elective care with 9.6 x the non-diabetes level for T1DM and 3.7 x non-diabetes level for T2DM.
51 The elective treatment costs were 4.7 x for T1DM and 2.8x higher for T2DM than for non-
52 diabetes.
53
54
55
56
57
58
59
60

Table 3: Results The numbers and activities associated with 6,791 GP practices that had provided both HES activity and NDA data.

	TOTAL	Non-Diabetes	T1DM	T2DM	T2 Age Adjust	Net T1DM ⁴	Net T2DM incl Age	DM Imp ⁵ % Total	T1 as % DM	Multiple of Non-Diabetes Unit	
										T1	T2 Age Adjusted
Population ,000	56,915	53,796	239	2,880							
Hospital Spend (£million):											
Non Elective Tariff	£8,859	£6,756	£288	£1,815	£479	£258	£975	14%	21%	9.6	3.7
Elective Tariff	£9,270	£7,809	£164	£1,297	£140	£129	£739	9%	15%	4.7	2.8
Outpatient (@£125each)	£14,305	£12,503	£291	£1,511	£210	£235	£632	6%	27%	5.2	1.9
A&E (@£160each)	£3,159	£2,885	£42	£232	£35	£29	£42	2%	41%	3.2	1.3
TOTAL	£35,593	£29,953	£784	£4,855	£864	£651	£2,388	9%	21%	5.9	2.5
Admissions & Bed days: ,000											
Non Elective Bed-days	14,204	10,980	445	2,779	-892	396	1,299	12%	23%	9.1	3.2
Non-Elective Adm ¹	5,853	4,742	163	948	-246	142	448	10%	24%	7.7	2.8
Elective Bed-days	10,462	8,924	194	1,345	-457	154	409	5%	27%	4.9	1.9
Elective Adm ON ²	4,774	3,949	191	635	17	173	441	13%	28%	10.9	3.1
Elective Adm DC ³	6,799	5,858	74	866	-37	48	515	8%	9%	2.9	2.6
Length of Stay Days (LOS):										% of Non-D	
Non-Elective LOS	2.43	2.32	2.72	2.93		2.72	2.69			118%	116%
Elective LOS	2.19	2.26	1.01	2.12		1.01	1.36			-55%	-40%
Attendances: ,000											
Outpatient	114,439	100,024	2,324	12,091	-1,682	1,879	5,054	6%	27%	4.8	1.9
A&E	19,742	18,034	260	1,448	-219	180	264	2%	41%	3.1	1.3

¹Adm = Admissions ²ON= Overnight ³DC= Daycase ⁴Net = Total after taking away non-diabetes costs and age factor ⁵Imp=Impact of additional resources for DM

Total Inpatient Tariff Charges

The total admission tariff charges for people with diabetes is £3.5 billion/year. £2.1 billion is for non-elective/emergency and £1.4 billion elective work. Of this £0.9 billion would be chargeable for average non-diabetes activity plus £0.6 billion can be associated with the older age of the T2DM. Therefore the total net additional costs are £2 billion/year - this splits as £0.4 billion T1DM (£1,620/person) and £1.6 billion T2DM (£595/person).

For the non-diabetes population, non-elective/emergency tariff charges are 46% of the total admission charges. For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion or 60% of the total net excess; this splits as £3,090/person T1DM and net £340/person/T2DM.

Bed Occupancy

The recorded 24.7 million bed days is equivalent to 67,577 fully occupied beds; of these 13,047 or 19.3% were taken by people with either T1DM or T2DM. 6,858 beds occupied (10%) can be explained by the expected health requirements of older age people. The remaining 6,183 (9.1% of total) can be considered a direct consequence of the additional comorbidities associated with diabetes. Of these 1,645 (26% of DM excess total) excess beds are occupied by T1DM.

Closer examination of beds occupied by patients admitted in non-elective/emergency circumstances revealed that out of the total 38,914 fully occupied beds 8,832 (22.6%) were occupied by people with diabetes, and allowing for the expected 4,576 normal and older age, the excess in emergency is 4,256 beds - these are 11% of the total non-elective beds and 68% of the overall excess diabetes beds. It is also worth noting that 1,174 of the excess non-elective beds are taken by T1DM people, making up 70% of the total 1,645 T1DM excess beds.

Length of Stay (LOS) – excluding day cases

An average length of stay for both elective overnight and emergency admissions can be calculated by dividing their total bed-days for both T1DM and T2DM (age-adjusted) by their total number of overnight admissions for T1DM and T2DM (age-adjusted). These values can then be compared to the two different LOSs for the non-diabetes population.

The non-elective LOS for both T1DM and T2DM are only around 10% longer than non-diabetes, so most of the higher non-elective or emergency bed occupancy in diabetes must come from an increased rate of admission rather than LOS.

The elective LOS data are intriguing with the average overnight elective length of stay for T1DM is at 1.0 day/person around 50% of the non-diabetes. For T2DM at 1.46 days/person, LOS is 62% of the non-diabetes LOS. This suggests that these patients are receiving higher numbers of planned short overnight admissions across a number of specialities, to treat some of the consequences of their condition.

Elective Daycase

The evidence shows that elective day-case admissions for both T2DM (age-adjusted) and T1DM are around 2.5 times the level of the non-diabetes patients. This will include day case podiatry procedures, ophthalmology and dialysis day-case attendances. This suggests that the increase in diabetes associated comorbidities does also increase the amount of elective treatment levels that people with diabetes require.

Outpatient Attendances

There was a big difference between the additional number of outpatient attendances that a person with T1DM patients showed at 4.8 times the non-diabetes attendances compared to the 1.8 times for T2DM. This might be due to the larger number of ongoing checks are being given to people with T1DM for eye, foot and renal complication management. The total additional outpatient attendances provided to people with diabetes to cover all the consequences of their condition was estimated at 6.9 million or 6% of all outpatient

1
2
3 attendances. At an estimated average reference cost of £125/attendance, this costs the NHS
4 total £825 million/year.
5
6
7
8

9 A&E Attendances

10
11 A&E attendances for T1DM were 3.1 times higher and T2DM 1.3 times higher than non-
12 diabetes. The total additional estimated diabetes related A&E attendances at 440 thousand
13 was 2% of all the A&E attendances in England in 2017/18. At an average cost of
14 £160/attendance, this costs the NHS a total of £70 million/year.
15
16
17
18
19
20

21 Discussion

22
23 There has been much discussion about the true cost of diabetes and its complications to the
24 NHS. There is already significant investment in managing the 3.2 million people identified with
25 diabetes. The spend on glycaemic control medication alone in 2017_18 was over £1 billion.
26 This analysis shows that additional costs of provision of hospital services due to their diabetes
27 comorbidities is £3 billion above those for non-diabetes and that within this T1DM have three
28 time as much cost impact as T2DM. We have not included other forms of diabetes such as
29 maturity onset diabetes of the young (MODY) or secondary diabetes in our analysis, as the
30 numbers of people with these conditions are likely to be quite low at individual GP practices
31 and coding of diagnosis is likely to vary.
32
33
34
35
36
37
38
39

40 In order to account for the variable rate of identification of T2DM across GP practices we have:

- 41 a) In the hospital data captured activity for all those patients whose hospital record as
42 having diagnosis diabetes at any visit during the previous 2 years
- 43 b) In the practice data captured local total local populations having records of diabetes
44 diagnosis
- 45 c) In the latter, there will be an identification gap as practices will over or under
46 diagnose compared to average. This gap will make those practices costs/head
47 relatively higher or lower and so we make it clear that some of these costs may be
48 due to over/under diagnosis
- 49 d) Also by calculating and bringing this identification gap into the age impact calculation,
50 we remove this potential confounder from age impact
51
52
53
54
55
56
57
58

1
2
3
4
5 Hex et al (2012) (9) in “Estimating the current and future costs of Type 1 and Type 2 diabetes
6 in the UK, including direct health costs and indirect societal and productivity costs” estimated
7 the total secondary care costs at £7.7billion with excess in-patient days at a cost £1.8 billion
8 of which 99% was on T2DM. Marion Kerr in ‘Inpatient Care for People with Diabetes: The
9 Economic Case for Change for Insight Health Economics’ November 2011 (10) estimated the
10 additional impact at £573 million – £686 million. Neither of these previous analyses took
11 account of the age distribution difference between T2DM individuals and the non-diabetes
12 population as we have done here.
13
14
15
16
17
18
19
20

21 Hex et al. (8) also indicated that less than 25% of that diabetes treatment cost relates to the
22 costs of management of diabetes, with the rest being accounted for by the costs of treating
23 the complications of diabetes, which in one sense could be seen as ‘adverse events’. Another
24 factor highlighted in this paper is that the indirect costs of diabetes are considerably higher
25 than the direct costs and many relate to a cost to the individual with diabetes or to their carers.
26 Cost estimates for productivity and social costs are often opportunity costs, such as time lost
27 that could be spent on other activities (9). Furthermore, one quarter of care home residents in
28 the UK have T2DM (11). Access issues, where there are frailty and mobility problems
29 preventing routine GP or hospital appointment visits can result in services being quite variable
30 in delivery from one area to another (12).
31
32
33
34
35
36
37
38
39

40 An International Diabetes Federation study (13) showed that people with diabetes have
41 medical costs that are two to three times more than age and sex matched patients without
42 diabetes ie that if the average healthcare cost per person without diabetes is \$1,000 (£787),
43 for a similar person with diabetes the cost will be \$2,000-\$3,000. These figures are not
44 dissimilar to those reported in our study - of £560/non-diabetes person compared to
45 £1,810/person with diabetes. The significant excess of non-elective and elective activity and
46 costs for T1DM individuals is indicative of the complexities of management of this condition
47 and is related to the fact that many people with T1DM do not achieve target glycaemic control
48 with hypoglycaemia, a frequent cause of Hospital A/E attendance (14).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There is also large pressure on hospital beds and especially with emergency admissions. That
4 11% of emergency beds are occupied by patients being admitted through the direct
5 consequences their diabetes and 27% of these are T1DM, shows that supporting patients in
6 managing their diabetes remains a clear focus for primary care with T1DM remaining a very
7 important aspect. Length of stay as reported here is also a factor and this can be impacted
8 significantly by effective deployment of diabetes specialist nurses on wards (15).
9
10
11
12
13
14

15 The total additional outpatient attendances provided to people with diabetes to cover all the
16 consequences of their condition was estimated at 6.9 million or 6% of all outpatient
17 attendances. This might be due to the larger number of ongoing checks that are being given
18 to people with T1DM for eye, foot and renal complication management and to many people
19 with T1DM. This also highlights a possible opportunity to deliver more of these services in the
20 community rather than in the hospital for these patients.
21
22
23
24
25
26
27

28 The higher number of elective day-case, elective and A/E attendances likely are a
29 consequence of management of diabetes complications and comorbidities in both T1DM and
30 T2DM.
31
32
33
34
35

36 We know that people with diabetes are constantly managing their condition on a daily basis
37 but may only come into contact with healthcare professionals a couple of times a year.
38 Therefore education programmes that give people the knowledge and motivation to manage
39 their condition have value. For people with T1DM, Dose Adjustment Normal Eating (DAFNE)
40 (16) is an education course that trains people to estimate the carbohydrate in each meal and
41 to inject the right dose of insulin. A cost-effectiveness analysis (17) based on economic data
42 from randomised control trials on DAFNE and similar programmes in Germany and Austria
43 shows very good results. A seven year follow-up on UK patients who went on a DAFNE course
44 showed that their glycaemic control remained better than a similar group who had not been
45 on the course (18). Over 10 years, structured treatment and teaching programmes save
46 £2,200 per patient. The majority of the savings arose from avoiding dialysis and foot ulceration.
47
48
49
50
51
52
53
54
55

56 Education for people with T2DM is also cost-effective. Data from a leading education
57 programme, X-PERT, shows the costs are outweighed by savings in cardiovascular and
58
59
60

1
2
3 diabetes medication (19). A systematic review rated X-PERT as very cost-effective (20).
4 Another major education programme, Diabetes Education and Self Management for Ongoing
5 and Newly Diagnosed (DESMOND) (21), is also effective with the key benefits being
6 reductions in weight and smoking rate (22).
7
8
9

10
11
12 In our recent papers (6,7) we showed that access to expert patient programmes can result in
13 significant improvements in glycaemia control as can informed choice of diabetes medication.
14 If achieved, such improvements in glycaemia could have the potential to reduce hospital costs
15 in the longer term.
16
17
18

19
20
21 Healthcare systems influence a broad range of treatment decisions, both directly, via
22 implemented policies/guidelines, and indirectly through the impact of shorter duration of
23 clinical appointments and patients' perceptions of their healthcare needs. We hope that this
24 paper will be helpful to those who direct policy in healthcare both in the UK and elsewhere in
25 the world.
26
27
28

29 30 31 32 **Conclusion**

33
34 People with diabetes have a significant impact on hospital activity including management of
35 diabetes related complications. They are admitted more often especially as emergencies and
36 stay on average for longer. People with T1DM, although 10% of the people with diabetes have
37 more than threefold the impact of T2DM, so require more special attention. However, people
38 with T2DM have a wider range of comorbidities and so can be more complex.
39
40
41
42

43
44
45 Improved management of T1DM and T2DM in primary care in terms particularly of measures
46 to prevent the longer term development of complications, can reduce the level of hospital
47 activity and hospital costs. The role of the secondary care specialist team in supporting primary
48 care and ensuring that most people with diabetes are being well managed not just focussing
49 on the smaller in number hardest to treat group will be a key factor in improving primary care
50 management outcomes. This could potentially reduce the excess hospital activity and
51 attendant costs consequent on managing the longer-term consequences of all forms of
52 diabetes.
53
54
55
56
57

Figure legends:

Figure 1: T2DM Identification. T2DM Identification. Statistical model linking % of T2DM to chosen practice factors. Factors contributing related to higher T2DM prevalence are on the right of the figure.

Figure 2A: Age Distribution (proportion at a particular age) in the general population by diabetes type and proportion aged >65 years in hospital patients.

Figure 2B: Impact in practices non-diabetes population of Age% > 75 years old on total hospital costs/non-diabetes population

Figure 3: Figure 3A-3E shows the results from 5 multivariate regression models linking to selected practice factors for T2DM related hospital activity

Figure 4: Comparison of hospital activity between non-diabetes and T1DM (split by the impact of population and condition) and T2DM (split by impact population, age, and condition)

References

1. WHO Global Report on Diabetes 2016. Accessed at <https://apps.who.int/iris>: Accessed on 31 May 2019
2. National Diabetes Inpatient Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit>: Accessed 25 May 2019
3. NHS Digital HES data at <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>: Accessed 21 May 2019
4. National Diabetes Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit>: Accessed 25 May 2019
5. *HERC (2018) Yorkshire and the Humber Public Health Observatory Data* https://www.herc.ox.ac.uk/health_datasets/...data.../yorkshire-and-the-humber-public-health-observatory-indicator-search-tool: Accessed 26 May 2019
6. Heald AH, Livingston M, Malipatil N, Becher M, Craig J., Stedman M, Fryer A, Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit. *Diabetes Obes Metab* 2017; 20: 185-194
7. Heald AH, Livingston M, Fryer A, Moreno GYC, Malipatil N, Gadsby R, Ollier W, Lunt M, Stedman M, Young RJ. Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit. *Diabet Med* 2018; 35: 63-71
8. NHS Improvement 2017_18 Hospital Service Reference costs <https://improvement.nhs.uk/resources/reference-costs/#rc1718>
9. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs York Health Economics Consortium Ltd, University of York, *Diabetic medicine* 2012; 29: 855-62
10. Inpatient Care for People with Diabetes: The Economic Case for Change Marion Kerr Insight Health Economics, at https://www.diabetes.org.uk/resources-s3/2017-1_1.pdf: Accessed 14 June 2019
11. www.kingsfund.org.uk/sites/default/files/field/field_document/managin_g-people-long-term-conditions-gp-inquiry-research-paper-mar11.pdf: Accessed 23 May 2019
12. Good clinical practice guidelines for care home residents with diabetes. (January 2010). Available at: http://www.diabetes.org.uk/About_us/Position-statements--recommendations/Care-recommendations/Good-clinical-practice-guidelines-for-care-home-residents-with-diabetes: Accessed 25 May 2019
13. Zhang et al. Economic impact of diabetes in Diabetes Atlas fourth edition. International Diabetes Federation: Brussels. 2009. http://www.idf.org/sites/default/files/Economic_impact_of_Diabetes.pdf: Accessed 26 May 2019
14. Wang H, Donnan PT, Leese CJ, Duncan E, Fitzpatrick D, Frier BM, Leese GP. Temporal changes in frequency of severe hypoglycemia treated by emergency medical services in

1
2
3 types 1 and 2 diabetes: a population-based data-linkage cohort study. Clin Diabetes
4 Endocrinol 2017; 3: 7
5

6 15. <https://diabetestimes.co.uk/diabetes-nurses-group-celebrates-anniversary-2/>: Accessed 23
7 June 2019
8

9 16. Lawton J, Rankin D, Cooke D, Elliott J, Amiel S, Heller S. UK NIHR DAFNE Study Group.
10 Patients' experiences of adjusting insulin doses when implementing flexible intensive insulin
11 therapy: a longitudinal, qualitative investigation. Diabetes Res Clin Pract. 2012 98: 236-42
12

13 17. Shearer et al. Cost-effectiveness of flexible intensive insulin management to enable dietary
14 freedom in people with Type 1 diabetes in the UK. Diabetic Medicine 2004; 21: 460-7
15

16 18. Gunn, D, Mansell, P. Glycaemic control and weight seven years after DAFNE structured
17 education in Type 1 diabetes. Diabetic Medicine 2012; 29: 807-12
18

19 19. Deakin, T. The diabetes pandemic: is structured education the solution or an unnecessary
20 expense? Practical Diabetes 2011, 28 NO. 8. Available at:
21 <http://onlinelibrary.wiley.com/doi/10.1002/pdi.1635>: Accessed 29 May 2019
22

23 20. Jacobs-Van Der Bruggen MAM, et al. Cost-effectiveness of lifestyle modification in diabetic
24 patients. Diabetes Care 2009; 32:1453–8.
25

26 21. Gillett et al. Delivering the diabetes education and self management for ongoing and newly
27 diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost
28 effectiveness analysis. BMJ (2010)
29

30 22. Davies MJ, et al. Effectiveness of the diabetes education for ongoing and newly diagnosed
31 (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised
32 controlled trial
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Transparency statement

Dr Heald as the corresponding author affirms that this is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics Statement

As we used publicly available and GP level data, with no individual patient data, it was not necessary to seek Ethics Approval for this study. This was not a clinical trial.

Funding

The relevant HES data was extracted from NHS Digital Hospital Episode Statistics by Wilmington Healthcare and provided by NAPP Pharmaceuticals.

Role of the Sponsor

There was no research sponsor for this study

Dissemination of study results to participants

Dissemination to specific participants will not be possible as all data was anonymised and at a GP practice level.

Patient Consent

This was not applicable as we analysed practice level data here.

Data Availability

In most cases publicly available data was used for the analysis. The Hospital Episode Data and filtration by Patient Diagnosis can be obtained through a suitable NHS Digital data research application. <https://digital.nhs.uk/services/data-access-request-service-dars>.

Duality of interest

No author has anything to disclose in relation to conflict of interest.

Contribution Statement

MS, MD, and AH conceived the study. MS collected the data. MS and MLu conducted the data analysis. MS, MLi, MD, AF, CD, MG, RG, SGA, GR and AH all contributed to the writing of the paper. SGA, GR, RG, AF and MG provided an overview of the manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Regression model results for GP practice-level prevalence of T2DM, regression factors are then be used to calculate target denominator in practice case identification %

142x105mm (300 x 300 DPI)




Figure 2A: Age Distribution and % attending hospital with age >65 for Non-Diabetes, T1DM and T2DM populations

Figure 2B: Correlation between GP practices % Non-Diabetes population Age >75 and total Non-Diabetes hospital costs/head population

120x186mm (300 x 300 DPI)




Figure 3A-E: Regression model for T2DM linking hospital costs/activity to other practice factors including age

182x211mm (300 x 300 DPI)




Figure 4: Splitting total hospital costs and activities between non-diabetes, T1DM and T2DM populations, including for impact of the T2DM age difference and DM condition

235x103mm (300 x 300 DPI)

BMJ Open

The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033231.R2
Article Type:	Original research
Date Submitted by the Author:	10-Mar-2020
Complete List of Authors:	Stedman, Mike; Res Consortium Lunt, Mark; University of Manchester, ARC Epidemiology Unit Davies, Mark; Res Consortium Livingston, Mark; Walsall Healthcare NHS Trust, Clinical Biochemistry Duff, Christopher; University Hospitals of North Midlands NHS Trust, Department of Clinical Biochemistry Fryer, Anthony; Keele University, Institute for Science & Technology in Medicine Anderson, Simon; University of the West Indies Cave Hill Campus, The George Alleyne Chronic Disease Research Centre Gadsby, Roger ; University of Warwick Warwick Medical School Gibson, Martin; Salford Royal Hospital, Endocrinology and Diabetes Rayman, Gerry; Ipswich Hospital NHS Trust, The Ipswich Diabetes Centre and Research Unit Heald, Adrian; Leighton Hospital, Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Health economics, Public health, Diabetes and endocrinology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, HEALTH ECONOMICS, PUBLIC HEALTH, Hospital

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 The cost of hospital treatment of Type 1 diabetes (T1DM) and Type 2
5 diabetes (T2DM) compared to the non-diabetes population: a detailed
6 economic evaluation
7
8
9

10 Mike Stedman¹, Mark Lunt², Mark Davies¹, Mark Livingston³, Christopher J Duff^{4,5},
11 Anthony Fryer^{4,5}, Simon G Anderson², Roger Gadsby⁶, Martin Gibson², Gerry
12 Rayman⁷, Adrian Heald^{1,8}
13
14
15
16
17
18

19 ¹Res Consortium, Andover, Hampshire; ²The School of Medicine and Manchester
20 Academic Health Sciences Centre, University of Manchester, Manchester;
21 ³Department of Clinical Biochemistry, Black Country Pathology Services, Walsall
22 Manor Hospital, Walsall; ⁴Department of Clinical Biochemistry, University Hospitals
23 of North Midlands NHS Trust, Stoke on Trent; ⁵Institute for Science and Technology
24 in Medicine, Keele University; ⁶Warwick Medical School, University of Warwick,
25 ⁷Department of Diabetes and Endocrinology, Ipswich General Hospital, ⁸Department
26 of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK
27
28
29

30 Corresponding author: Dr Adrian Heald
31 Department of Diabetes and Endocrinology,
32 Salford Royal Hospital, Salford, UK.
33 M6 8HD
34
35

36 Telephone: +44 161 206 5157
37

38 Email: adrian.heald@manchester.ac.uk
39

40 Manuscript word count (main text): 3998
41
42
43

44 Keywords: Type 2 diabetes, Type 1 diabetes, Hospital, HES, Cost, GP practice
45
46
47
48
49
50
51
52
53

54 Key messages:
55

- 56 • We aimed to more exactly quantify the net impact of diabetes on the different
57 aspects of healthcare provision in hospitals in England.
- 58 • The study captured around 90% of the hospital activity and £36 billion/year of
59 hospital spend.
60

- Once the normally expected costs including the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care costs. This equates to £560/non-diabetes person compared to £3,280/person with T1DM and £1,686/person with T2DM.
- There are still opportunities to reduce potential future additional costs further through increased investment in local services and medication for diabetes treatment.

Article Summary:

Strengths and Limitations of the Study

Strengths of this study

- We were able to look at national level data across nearly 5500 GP practices in relation to hospital activity. The analysis covered more than 90% of hospital costs in England.

Limitations of this study

- Any conclusions drawn must account for the fact that our findings are based on association, not definite causation.
- Inherent in this real-world analysis methodology are potential confounding factors that are inherent in any retrospective study. Nevertheless, our design was such as to minimise the potential impact of such factors.

Abstract

Objectives

Other than age, diabetes is the largest contributor to overall health care costs and reduced life expectancy in Europe. This paper aims to more exactly quantify the net impact of diabetes on different aspects of healthcare provision in hospitals in England, building on previous work that looked at the determinants of outcome in T1DM and T2DM.

Setting

NHS Digital Hospital Episode Statistics (HES) in England was combined with the National Diabetes Audit (NDA) to provide the total number in practice of people with T1DM/T2DM.

Outcome measures

We compared differences between T1DM/T2DM and non-diabetes individuals in relation to hospital activity and associated cost.

Results

The study captured 90% of hospital activity and £36 billion/year of hospital spend. The NDA Register showed that out of a total reported population of 58 million, 2.9 million (6.5%) had T2DM and 240 thousand (0.6%) had T1DM. Bed day analysis showed 17% of beds are occupied by T2DM and 3% by T1DM.

The overall cost of hospital care for people with diabetes is £5.5 billion/year. Once the normally expected costs including the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care costs. This equates to £560/non-diabetes person compared to £3,280/person with T1DM and £1,686/person with T2DM.

For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion with additional estimated diabetes-related A&E attendances at 440,000 costing the NHS £70 million/year.

T1DM individuals required five times more secondary care support than non-diabetes individuals. T2DM individuals, even allowing for the age, require twice as much support as non-diabetes individuals.

Conclusions

This analysis shows that additional costs of provision of hospital services due to their diabetes comorbidities is £3 billion above those for non-diabetes and that within this

1
2
3 T1DM have three time as much cost impact as T2DM. We suggest that supporting
4 patients in diabetes management may significantly reduce hospital activity.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Other than age, diabetes is the largest contributor to overall health care costs and reduced life expectancy in Europe (1). People with Type 1 (T1DM) and Type 2 (T2DM) diabetes require much higher levels of hospital support than their non-diabetes counterparts. Health care provision in hospital can be broken down into four main areas: 1) planned/elective including day-case admissions (Planned), 2) emergency/non-elective admissions (Emergency), 3) accident & emergency (A&E) attendances and 4) outpatient consultations/attendances (Outpatient). Each of these different classes must be managed appropriately by clinicians and hospital administrators and the relevance of diabetes to this planning may be different.

The National Diabetes Inpatient Audit (2) has shown that 18% of all hospital beds on any one day are occupied by people who have a diagnosis of diabetes (2) compared to a 7% prevalence of all diabetes in the adult population of England. This may significantly overstate the impact of the condition as over 90% of people with diabetes have T2DM, which generally occurs much later in life so that the cohort is significantly older than the general population – as such their normal healthcare requirements would increase significantly with age.

NHS Digital publishes the general practitioner (GP) practice patient register split into age groups and can provide practice level extracts from hospital episode statistics (HES) of the amount of different practice activities for people who have a recorded diagnosis of T1DM or T2DM and those that do not have such a diagnosis (3). The National Diabetes Audit publish the numbers and ages of people with either T1DM or T2DM in each practice (4) also split into age groups. Other practice characteristics such as ethnicity, social deprivation, location, are also publicly available (5).

The NHS in England publishes a significant amount of data at a GP practice level and we have previously described the impact of a variety of population, service and prescribing factors on outcomes (6,7). We have previously looked at the determinants of outcome in T1DM and T2DM in GP practices in England (6,7). It was felt that this approach could be used to quantify and so adjust for the effect of age on different services that are provided in hospital to T2DM individuals and therefore

1
2
3 achieve a much more accurate evaluation of the actual net cost of diabetes,
4 including all associated comorbidities to the health service.
5
6
7

8 9 **Aims**

10
11 This paper aims to more exactly quantify the net impact of diabetes on the different
12 aspects of healthcare provision in hospitals in England.
13
14
15

16 At GP practice level, we took the allocation of the different elements of hospital costs
17 associated with the diagnosis of either T2DM or T1DM while adjusting for the
18 difference in the T2DM age profile from the general population. We wished to use
19 this analysis to provide a clearer focus for diabetes services to determine which
20 elements of care they can focus on, in order to improve outcomes. Specifically, we
21 compared differences between T1DM/T2DM and non-diabetes individuals in relation
22 to hospital activity and the associated costs.
23
24
25
26
27
28
29
30
31

32 33 **Methods**

34 Individual patients who had a diagnosis of either T1DM or T2DM and their age and
35 practice code were identified within the NHS Digital Hospital Episode Statistics
36 (HES) data for 2016_17 and 2017_18. The sum of annual activity of the different
37 services, including emergency, elective, A&E and outpatient care, was then
38 extracted from the NHS Digital HES for each general practice for all those patients
39 with a diagnosis of T1DM or T2DM and the non-diabetes individuals in 2017_18.
40 Emergency and elective activity were shown as totals for the number of unique
41 patients, admissions, overall bed-days, and the total national tariff charged, while
42 only the number of unique patients and total attendances were provided for
43 outpatient and A&E activity. The completeness of data was checked by looking at
44 the national totals for the year reported within the reference costs.
45
46
47
48
49
50
51
52
53
54

55 The actual total population of T1DM and T2DM individuals and their age groups at
56 the GP practice level was taken from NHS Digital National Diabetes Audit (4). Public
57 Health England publishes the patient numbers and age profile of each GP practice
58
59
60

1
2
3 from this total. The age profile for non-diabetes patients was calculated by
4 subtracting the total diabetes population.
5
6
7

8 The demographic and locational data for each practice including social deprivation,
9 population density (urban/rural), Latitude (Northerliness) were taken from the Office
10 of National Statistics (ONS) (5). The % minority ethnicity was also determined.
11
12
13

14
15 The total overall hospital costs for each practice in each of the three classes (T1DM,
16 T2DM, and non-diabetes) were calculated by adding the provided total elective &
17 non-elective tariff charges to the Outpatient and Accident & Emergency attendances
18 each multiplied by the national overall average cost/attendance taken from the 2017-
19 18 national reference costs.
20
21
22
23

24
25 For each of the T1DM, T2DM and Non-diabetes population: Total Hospital Costs =
26 Total recorded Elective Tariff Charges + Total recorded Non-Elective Tariff Charges+
27 Total recorded Outpatient Attendances x Average annual Outpatient tariff
28 cost/attendance + Total recorded Accident & Emergency attendances x average cost
29 / attendance (both taken from the 2017-18 national reference costs).
30
31
32
33
34

35
36 The number of practices included in the study was limited to those for which all the
37 data sets were available plus if there were more than 200 T2DM patients or more
38 than 20 T1DM patients on their register (5468 GP practices).
39
40
41
42

43 Practices that identify people earlier in the course of their T2DM increase their
44 numbers and pro-rata this reduces the associated average hospital costs/person, to
45 include for this a "T2DM %case identification" factor was calculated. Our statistical
46 model took account of this and linked the actual recorded T2DM register as % of the
47 total practice population to the practice age, gender, ethnicity, social disadvantage,
48 latitude, and main long-term condition disease prevalence. Based on this statistical
49 model an expected level of T2DM could be predicted. The difference between the
50 predicted and actual T2DM prevalence was taken as the local practice % case
51 identification. This factor was not required for T1DM as the onset of that condition is
52 more clearly delineated, so all people with this condition can be more easily
53 identified.
54
55
56
57
58
59
60

Patient and Public Involvement Statement

It was not appropriate or possible to involve patients or the public in this work given that we used general practice level summated data and related hospital outcome statistics.

Statistics

A stepwise multiple regression model was created using Excel with Analyse-it add-in linking as outcome level of hospital activity of each class/head of population for T1DM and T2DM at GP practice level to the:

- The same measure for the non-diabetes population
- % of non-diabetes population age >75
- % of either T1DM or T2DM
- % case Identification (T2DM)
- Population Density (pop/sq km)
- % Black and Minority Ethnicity (BME)
- Practice Size
- % Prevalence of T2DM
- Latitude

To remove the effect of the age difference between T2DM and non-diabetes population on the cost impact of diabetes, the regression coefficient was applied to the difference between % on patients over 75 in T2DM and the non-diabetes population, to give a “net” T2DM disease impact on each of the activities and cost levels including:

- Overall Costs
- Emergency Admissions, Bed days & Tariff
- Elective Admissions, Day case, Bed days & Tariff
- A&E Attendances
- Outpatient Attendances

To highlight the impact of the condition the activity/person for T1DM and T2DM was also shown as a ratio to the non-diabetes activity/person.

As diabetes can have many wide-ranging health impacts establishing the overall additional all-cause hospital costs of diabetes on top of expected normal healthcare needs is difficult. Using a practice population based approach allows us to allow for confounding factors such as age and disease identification. However, it remains a statistical analysis relying on large amounts of data entered during clinical treatments so it will contain normal administrative errors. Nevertheless, it is hoped that both the scale of this data capturing over 160 million episodes and as these errors can be either over or under reported that the outcomes should correspond to the actual values.

Results

The study (See Table 1) captured around 90% of the hospital activity data for England in 2017/18. The missing 10% could be explained by the difference in definitions between the different analyses (i.e. outpatient attendances and episodes which include more than one attendance). The tariff difference between the reference known costs of hospital T1DM/T2DM management and extracted HES of just under £7billion could relate to other commercial costs or activities not captured within the HES data extraction.

Table 1: Data Captured in Study

2017_18	Reference Costs	Extracted HES	Captured
Organisation providing returns	152		
Bed-days	26,462,497	25,932,385	98%
Tariff Charged	£26,219,369,965	£19,392,269,892	74%
Outpatient Attendance	87,714,235	119,758,272	137%
A&E Attendances	19,950,458	20,737,416	104%

The NDA Register showed that out of a total population of 56 million in England, 2.9 million (6.5%) had T2DM and 270 thousand (0.7%) had T1DM. The bed day analysis confirmed that 17% of beds were occupied by T2DM and 3% by T1DM at a total of 20% on average of bed occupancy similar to that reported in the National Inpatient Audit (2).

The National average reference 2017_18 costs/event for both consultant and non-consultant led outpatient appointments is £125/attendance (8). The national average reference costs for the variety of A&E attendances including all the activities were £160/attendance (8).

Table 2 Scope of Study

2017_18	Practices		Population		NDA T2		NDA T1
Total	7,255		59,005,024		2,914,825		243,090
Complete Data	6,676	92%	55,924,632	95%	2,835,540	97%	236,025
T2>200	5,468	75%	51,352,503	87%	2,656,850	91%	

Included into the study (Table 2) were practices for which there was enough data and to reduce the impact of single hander practice outliers and decrease the variance only practices with more than 200 T2DM patients were included in the estimation of age impact. This removed 18% of practices and 6% of the T2DM population.

The results of the expected prevalence calculation are shown in Figure 1. GP practices with a higher proportion of black and minority ethnicity (BME) ethnicity individuals, people with hypertension and coronary artery disease plus an older age profile had higher proportions of T2DM individuals. The statistical model based on these factors accounted for 74% of the variation in T2DM prevalence across GP practices in England. Higher proportions of black and minority ethnicity individuals, individuals with a history of hypertension, coronary artery disease and aged 65 or over have the strongest association with higher T2D prevalence. A "T2DM Case Identification" for each practice was then calculated from the actual prevalence of T2 divided by the expected value.

Figure 2A shows the age profile (proportion at a particular age) of non-diabetes, T1DM, and T2DM in the England general population. For T2DM the age distribution is considerably different from the non-diabetes population, while the T1DM age distribution is close to the non-diabetes population. The figure also shows the proportion of over 65 within each of these diagnostic categories (T1DM, T2DM, and non-diabetes) for hospital attendees. For hospital attendees, the proportion of

1
2
3 admissions in the over 65 age for T2DM at 66% was much higher than for non-
4 diabetes individuals at 22% and T1DM at 15%.
5
6
7

8 The age profile data showed that across all GP practices in England, for non-
9 diabetes 7% of people were aged >75 years and for people with T2DM 26% were
10 age >75 years old.
11
12
13

14
15 Figure 2B shows the variation of total hospital costs by the proportion of people on
16 the GP list >75 years old. The univariate linear regression based on GP practice
17 level total costs of hospital activity versus age profile of the practice shows that if 7%
18 of people were aged >75 years in the GP practice, that the expected total non-
19 diabetes population costs would be expected to be £568/person. However, if the
20 figure was 26% of people aged >75 years then the equivalent non-diabetes
21 population costs would rise to £884/person. This univariate analysis suggests that
22 the increased age of T2DM people accounts for up to £316/person of the cost
23 difference.
24
25
26
27
28
29
30
31

32 Multivariate Regression Analysis for T2DM hospital costs

33 Figure 3A-3E shows the results from 5 of the multivariate regression models used to
34 link the level of cost and activity / T2DM person to the main drivers from the practice
35 and levels for the non-diabetes populations including the age of both non-diabetes
36 and T2DM % >75.
37
38
39
40

41 Overall hospital costs / various practice populations were normal distributed with
42 skew and kurtosis factors for non-DM = 0.06 & 1.7; T2DM = 0.8 & 2.2 and T1DM =
43 1.6 & 2.7, mostly within the +/- 2 acceptable range
44
45

46 The variation captured in each model was between 0.26 and 0.63. The regression
47 analysis shows that the main driver for T2DM diabetes service costs and activity are:
48

- 49 • Equivalent service costs for the non-diabetes population
- 50 • Age % >75 of the T2DM population

51 For the factors associated with lower T2DM hospital costs:
52
53

- 54 • Prevalence % T2DM
- 55 • Age % >75 of the non-diabetes population
- 56 • T2DM % case identification

57
58
59
60 Minor Factors that had variable effects included:

- Social Deprivation
- Practice Size
- T2DM Prevalence
- %BME ethnicity
- Northerly latitude.
- Population Density (urban/rural)

Similar patterns were seen across hospital total costs, non-elective costs, elective costs, outpatient total attendances, and A/E total attendances.

To extrapolate the level of the age effect contained within the T2DM activity and costs, the multiple regression coefficient for the proportion of T2DM individuals aged >75 years was taken for each measure from the analysis and applied to the difference between the T2DM value of 26% >75 years vs 7% of the non-diabetes population >75 years old. The age-related impact on T2DM total acute costs difference/person is £300/person. This was similar to the £316 calculated by the univariate analysis.

Figure 4 highlights the relation of the diagnosis of T1DM and T2DM with the percentage of total hospital activity. While the numbers of T1DM are 0.42% and T2DM are 5.06% of the total background population, having allowed for the normal needs and influence of age, the net diabetes impact as a condition is 8.5% of hospital costs of the NHS (T1DM 1.8% + T2DM 6.7%). In making up this net total 13.9% are for emergency costs (T1DM 2.9% + T2DM 11%), 9.2% are for elective costs (1.4% T1DM + 7.8% T2DM), 6% are for outpatient attendances (1.6% T1DM + 4.4% T2DM) and 2.2% are for A&E attendances (0.9% T1DM and 1.3% T2DM). Overall diabetes patients are taking 19.3% of bed days, but after allowing for normal needs and age-related, then the additional consumption is 11.9% of emergency beds (2.8% T1DM + 9.1% T2DM) and 5.4% elective beds (1.5% T1DM + 3.9% T2DM).

Table 3 provides an overview of the costs of diabetes including the impact of age on T2DM. £35.6 billion/year of hospital spending is included in this analysis. This accounts for 66% of £53.7 billion total hospital income in England in 2017/18 with the overall cost of hospital care for people with diabetes being £5.6 billion/year. Once the

1
2
3 normally expected costs including the older age of T2DM hospital attenders are
4 allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care
5 costs. Of this £0.65 billion or 21% of the age-adjusted diabetes spend came from the
6 additional treatment provided to T1DM individuals who were only 8% of the total
7 diabetes population. This equates to £560/non-diabetes person compared to
8 £3,280/person with T1DM and £1,686/person with T2DM (of this £300 is associated
9 with the age difference so the net impact on hospital costs is £826/person).
10
11
12
13
14
15
16

17 T1DM individuals required 5.9 x as much secondary care activity as non-diabetes
18 individuals. For T2DM, having allowed for the age difference there is 2.5 x secondary
19 care activity as non-diabetes individuals. The main area for these costs difference
20 was the emergency / non-elective care with 9.6 x the non-diabetes level for T1DM
21 and 3.7 x non-diabetes level for T2DM. The elective treatment costs were 4.7 x for
22 T1DM and 2.8x higher for T2DM than for non-diabetes.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3: Results The numbers and activities associated with 6,791 GP practices that had provided both HES activity and NDA data.

	TOTAL	Non-Diabetes	T1DM	T2DM	T2 Age Adjust	Net T1DM ⁴	Net T2DM incl Age	DM Imp ⁵ % Total	T1 as % DM	Multiple of Non-Diabetes Unit	
										T1	T2 Age Adjusted
Population ,000	56,915	53,796	239	2,880							
Hospital Spend (£million):											
Non Elective Tarif	£8,859	£6,756	£288	£1,815	£-479	£258	£975	14%	21%	9.6	3.7
Elective Tarif	£9,270	£7,809	£164	£1,297	£-140	£129	£739	9%	15%	4.7	2.8
Outpatient (@£125each)	£14,305	£12,503	£291	£1,511	£-210	£235	£632	6%	27%	5.2	1.9
A&E (@£160each)	£3,159	£2,885	£42	£232	£-35	£29	£42	2%	41%	3.2	1.3
TOTAL	£35,593	£29,953	£784	£4,855	£-864	£651	£2,388	9%	21%	5.9	2.5
Admissions & Bed days: ,000											
Non Elective Bed-days	14,204	10,980	445	2,779	-892	396	1,299	12%	23%	9.1	3.2
Non-Elective Adm ¹	5,853	4,742	163	948	-246	142	448	10%	24%	7.7	2.8
Elective Bed-days	10,462	8,924	194	1,345	-457	154	409	5%	27%	4.9	1.9
Elective Adm ON ²	4,774	3,949	191	635	17	173	441	13%	28%	10.9	3.1
Elective Adm DC ³	6,799	5,858	74	866	-37	48	515	8%	9%	2.9	2.6
Length of Stay Days (LOS):										% of Non-D	
Non-Elective LOS	2.43	2.32	2.72	2.93		2.72	2.69			118%	116%
Elective LOS	2.19	2.26	1.01	2.12		1.01	1.36			-55%	-40%
Attendances: ,000											
Outpatient	114,439	100,024	2,324	12,091	-1,682	1,879	5,054	6%	27%	4.8	1.9
A&E	19,742	18,034	260	1,448	-219	180	264	2%	41%	3.1	1.3

¹Adm = Admissions ²ON= Overnight ³DC= Daycase ⁴Net = Total after taking away non-diabetes costs and age factor ⁵Imp=Impact of additional resources for DM

Total Inpatient Tariff Charges

The total admission tariff charges for people with diabetes is £3.5 billion/year. £2.1 billion is for non-elective/emergency and £1.4 billion elective work. Of this £0.9 billion would be chargeable for average non-diabetes activity plus £0.6 billion can be associated with the older age of the T2DM. Therefore the total net additional costs are £2 billion/year - this splits as £0.4 billion T1DM (£1,620/person) and £1.6 billion T2DM (£595/person).

For the non-diabetes population, non-elective/emergency tariff charges are 46% of the total admission charges. For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion or 60% of the total net excess; this splits as £3,090/person T1DM and net £340/person/T2DM.

Bed Occupancy

The recorded 24.7 million bed days is equivalent to 67,577 fully occupied beds; of these 13,047 or 19.3% were taken by people with either T1DM or T2DM. 6,858 beds occupied (10%) can be explained by the expected health requirements of older age people. The remaining 6,183 (9.1% of total) can be considered a direct consequence of the additional comorbidities associated with diabetes. Of these 1,645 (26% of DM excess total) excess beds are occupied by T1DM.

Closer examination of beds occupied by patients admitted in non-elective/emergency circumstances revealed that out of the total 38,914 fully occupied beds 8,832 (22.6%) were occupied by people with diabetes, and allowing for the expected 4,576 normal and older age, the excess in emergency is 4,256 beds - these are 11% of the total non-elective beds and 68% of the overall excess diabetes beds. It is also worth noting that 1,174 of the excess non-elective beds are taken by T1DM people, making up 70% of the total 1,645 T1DM excess beds.

Length of Stay (LOS) – excluding day cases

An average length of stay for both elective overnight and emergency admissions can be calculated by dividing their total bed-days for both T1DM and T2DM (age-

1
2
3 adjusted) by their total number of overnight admissions for T1DM and T2DM (age-
4 adjusted). These values can then be compared to the two different LOSs for the non-
5 diabetes population.
6
7

8
9
10 The non-elective LOS for both T1DM and T2DM are only around 10% longer than
11 non-diabetes, so most of the higher non-elective or emergency bed occupancy in
12 diabetes must come from an increased rate of admission rather than LOS.
13
14

15
16
17 The elective LOS data are intriguing with the average overnight elective length of
18 stay for T1DM is at 1.0 day/person around 50% of the non-diabetes. For T2DM at
19 1.46 days/person, LOS is 62% of the non-diabetes LOS. This suggests that these
20 patients are receiving higher numbers of planned short overnight admissions across
21 a number of specialities, to treat some of the consequences of their condition.
22
23
24

25 26 27 28 Elective Daycase

29 The evidence shows that elective day-case admissions for both T2DM (age-
30 adjusted) and T1DM are around 2.5 times the level of the non-diabetes patients. This
31 will include day case podiatry procedures, ophthalmology and dialysis day-case
32 attendances. This suggests that the increase in diabetes associated comorbidities
33 does also increase the amount of elective treatment levels that people with diabetes
34 require.
35
36
37
38
39
40
41

42 Outpatient Attendances

43 There was a big difference between the additional number of outpatient attendances
44 that a person with T1DM patients showed at 4.8 times the non-diabetes attendances
45 compared to the 1.8 times for T2DM. This might be due to the larger number of
46 ongoing checks are being given to people with T1DM for eye, foot and renal
47 complication management. The total additional outpatient attendances provided to
48 people with diabetes to cover all the consequences of their condition was estimated
49 at 6.9 million or 6% of all outpatient attendances. At an estimated average reference
50 cost of £125/attendance, this costs the NHS total £825 million/year.
51
52
53
54
55
56
57
58
59
60

A&E Attendances

A&E attendances for T1DM were 3.1 times higher and T2DM 1.3 times higher than non-diabetes. The total additional estimated diabetes related A&E attendances at 440 thousand was 2% of all the A&E attendances in England in 2017/18. At an average cost of £160/attendance, this costs the NHS a total of £70 million/year.

Discussion

There has been much discussion about the true cost of diabetes and its complications to the NHS. There is already significant investment in managing the 3.2 million people identified with diabetes. The spend on glycaemic control medication alone in 2017_18 was over £1 billion. This analysis shows that additional costs of provision of hospital services due to their diabetes comorbidities is £3 billion above those for non-diabetes and that within this T1DM have three time as much cost impact as T2DM. We have not included other forms of diabetes such as maturity onset diabetes of the young (MODY) or secondary diabetes in our analysis, as the numbers of people with these conditions are likely to be quite low at individual GP practices and coding of diagnosis is likely to vary.

In order to account for the variable rate of identification of T2DM across GP practices we have:

- a) In the hospital data captured activity for all those patients whose hospital record as having diagnosis diabetes at any visit during the previous 2 years
- b) In the practice data captured local total local populations having records of diabetes diagnosis
- c) In the latter, there will be an identification gap as practices will over or under diagnose compared to average. This gap will make those practices costs/head relatively higher or lower and so we make it clear that some of these costs may be due to over/under diagnosis
- d) Also by calculating and bringing this identification gap into the age impact calculation, we remove this potential confounder from age impact

1
2
3 Hex et al (2012) (9) in “Estimating the current and future costs of Type 1 and Type 2
4 diabetes in the UK, including direct health costs and indirect societal and productivity
5 costs” estimated the total secondary care costs at £7.7billion with excess in-patient
6 days at a cost £1.8 billion of which 99% was on T2DM. Marion Kerr in ‘Inpatient Care
7 for People with Diabetes: The Economic Case for Change for Insight Health
8 Economics’ November 2011 (10) estimated the additional impact at £573 million –
9 £686 million. Neither of these previous analyses took account of the age distribution
10 difference between T2DM individuals and the non-diabetes population as we have
11 done here.
12
13
14
15
16
17
18
19

20 Hex et al. (8) also indicated that less than 25% of that diabetes treatment cost
21 relates to the costs of management of diabetes, with the rest being accounted for by
22 the costs of treating the complications of diabetes, which in one sense could be seen
23 as ‘adverse events’. Another factor highlighted in this paper is that the indirect costs
24 of diabetes are considerably higher than the direct costs and many relate to a cost to
25 the individual with diabetes or to their carers. Cost estimates for productivity and
26 social costs are often opportunity costs, such as time lost that could be spent on
27 other activities (9). Furthermore, one quarter of care home residents in the UK have
28 T2DM (11). Access issues, where there are frailty and mobility problems preventing
29 routine GP or hospital appointment visits can result in services being quite variable in
30 delivery from one area to another (12).
31
32
33
34
35
36
37
38
39
40

41 An International Diabetes Federation study (13) showed that people with diabetes
42 have medical costs that are two to three times more than age and sex matched
43 patients without diabetes ie that if the average healthcare cost per person without
44 diabetes is \$1,000 (£787), for a similar person with diabetes the cost will be \$2,000-
45 \$3,000. These figures are not dissimilar to those reported in our study - of £560/non-
46 diabetes person compared to £1,810/person with diabetes. The significant excess of
47 non-elective and elective activity and costs for T1DM individuals is indicative of the
48 complexities of management of this condition and is related to the fact that many
49 people with T1DM do not achieve target glycaemic control with hypoglycaemia, a
50 frequent cause of Hospital A/E attendance (14).
51
52
53
54
55
56
57
58
59
60

1
2
3 There is also large pressure on hospital beds and especially with emergency
4 admissions. That 11% of emergency beds are occupied by patients being admitted
5 through the direct consequences their diabetes and 27% of these are T1DM, shows
6 that supporting patients in managing their diabetes remains a clear focus for primary
7 care with T1DM remaining a very important aspect. Length of stay as reported here
8 is also a factor and this can be impacted significantly by effective deployment of
9 diabetes specialist nurses on wards (15).

10
11
12 The total additional outpatient attendances provided to people with diabetes to cover
13 all the consequences of their condition was estimated at 6.9 million or 6% of all
14 outpatient attendances. This might be due to the larger number of ongoing checks
15 that are being given to people with T1DM for eye, foot and renal complication
16 management and to many people with T1DM. This also highlights a possible
17 opportunity to deliver more of these services in the community rather than in the
18 hospital for these patients.

19
20
21 The higher number of elective day-case, elective and A/E attendances likely are a
22 consequence of management of diabetes complications and comorbidities in both
23 T1DM and T2DM.

24
25
26 We acknowledge that we have not analysed ways in which the hospital costs of
27 diabetes could be reduced. We know that people with diabetes are constantly
28 managing their condition on a daily basis but may only come into contact with
29 healthcare professionals a couple of times a year. Therefore education programmes
30 that give people the knowledge and motivation to manage their condition have value.
31 For people with T1DM, Dose Adjustment Normal Eating (DAFNE) (16) is an
32 education course that trains people to estimate the carbohydrate in each meal and to
33 inject the right dose of insulin. A cost-effectiveness analysis (17) based on economic
34 data from randomised control trials on DAFNE and similar programmes in Germany
35 and Austria shows very good results. A seven year follow-up on UK patients who
36 went on a DAFNE course showed that their glycaemic control remained better than a
37 similar group who had not been on the course (18). Over 10 years, structured

1
2
3 treatment and teaching programmes save £2,200 per patient. The majority of the
4 savings arose from avoiding dialysis and foot ulceration.
5
6
7

8 Education for people with T2DM is also cost-effective. Data from a leading education
9 programme, X-PERT, shows the costs are outweighed by savings in cardiovascular
10 and diabetes medication (19). A systematic review rated X-PERT as very cost-
11 effective (20). Another major education programme, Diabetes Education and Self
12 Management for Ongoing and Newly Diagnosed (DESMOND) (21), is also effective
13 with the key benefits being reductions in weight and smoking rate (22).
14
15
16
17
18
19

20 In our recent papers (6,7) we showed that access to expert patient programmes can
21 result in significant improvements in glycaemia control as can informed choice of
22 diabetes medication. If achieved, such improvements in glycaemia could have the
23 potential to reduce hospital costs in the longer term.
24
25
26
27
28

29 Healthcare systems influence a broad range of treatment decisions, both directly, via
30 implemented policies/guidelines, and indirectly through the impact of shorter duration
31 of clinical appointments and patients' perceptions of their healthcare needs. We
32 hope that this paper will be helpful to those who direct policy in healthcare both in the
33 UK and elsewhere in the world.
34
35
36
37
38
39

40 **Conclusion**

41 People with diabetes have a significant impact on hospital activity including
42 management of diabetes related complications. They are admitted more often
43 especially as emergencies and stay on average for longer. People with T1DM,
44 although 10% of the people with diabetes have more than threefold the impact of
45 T2DM, so require more special attention. However, people with T2DM have a wider
46 range of comorbidities and so can be more complex.
47
48
49
50
51
52
53

54 While not a conclusion that we can draw directly from our analysis, it is possible that
55 improved management of T1DM and T2DM in primary care in terms particularly of
56 measures to prevent the longer term development of complications, may reduce the
57 level of hospital activity and hospital costs. The role of the secondary care specialist
58
59
60

20

1
2
3 team in supporting primary care and ensuring that most people with diabetes are
4 being well managed, not just focussing on the smaller in number hardest to treat
5 group will be a key factor in improving primary care management outcomes will be
6 critical in this endeavour.
7
8
9

10 11 **Figure legends:**

12
13 Figure 1: T2DM Identification. T2DM Identification. Statistical model linking % of
14 T2DM to chosen practice factors. Factors contributing related to higher T2DM
15 prevalence are on the right of the figure.
16

17 Figure 2A: Age Distribution (proportion at a particular age) in the general population
18 by diabetes type and proportion aged >65 years in hospital patients.
19

20 Figure 2B: Impact in practices non-diabetes population of Age% > 75 years old on
21 total hospital costs/non-diabetes population
22

23 Figure 3: Figure 3A-3E shows the results from 5 multivariate regression models
24 linking to selected practice factors for T2DM related hospital activity
25

26 Figure 4: Comparison of hospital activity between non-diabetes and T1DM (split by
27 the impact of population and condition) and T2DM (split by impact population, age,
28 and condition)
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. WHO Global Report on Diabetes 2016. Accessed at <https://apps.who.int/iris/>: Accessed on 31 May 2019
2. National Diabetes Inpatient Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit/>: Accessed 25 May 2019
3. NHS Digital HES data at <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>: Accessed 21 May 2019
4. National Diabetes Audit (2018) <http://content.digital.nhs.uk/diabetesinpatientaudit/>: Accessed 25 May 2019
5. *HERC (2018) Yorkshire and the Humber Public Health Observatory Data* https://www.herc.ox.ac.uk/health_datasets/...data.../yorkshire-and-the-humber-public-health-observatory-indicator-search-tool: Accessed 26 May 2019
6. Heald AH, Livingston M, Malipatil N, Becher M, Craig J., Stedman M, Fryer A, Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit. *Diabetes Obes Metab* 2017; 20: 185-194
7. Heald AH, Livingston M, Fryer A, Moreno GYC, Malipatil N, Gadsby R, Ollier W, Lunt M, Stedman M, Young RJ. Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit. *Diabet Med* 2018; 35: 63-71
8. NHS Improvement 2017_18 Hospital Service Reference costs <https://improvement.nhs.uk/resources/reference-costs/#rc1718>
9. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs York Health Economics Consortium Ltd, University of York, *Diabetic medicine* 2012; 29: 855-62
10. Inpatient Care for People with Diabetes: The Economic Case for Change Marion Kerr Insight Health Economics, at <https://www.diabetes.org.uk/resources-s3/2017-1-1.pdf>: Accessed 14 June 2019
11. www.kingsfund.org.uk/sites/default/files/field/field_document/managing-people-long-term-conditions-gp-inquiry-research-paper-mar11.pdf: Accessed 23 May 2019
12. Good clinical practice guidelines for care home residents with diabetes. (January 2010). Available at: http://www.diabetes.org.uk/About_us/Position-statements--recommendations/Care-recommendations/Good-clinical-practice-guidelines-for-care-home-residents-with-diabetes: Accessed 25 May 2019
13. Zhang et al. Economic impact of diabetes in Diabetes Atlas fourth edition. International Diabetes Federation: Brussels. 2009. http://www.idf.org/sites/default/files/Economic_impact_of_Diabetes.pdf: Accessed 26 May 2019
14. Wang H, Donnan PT, Leese CJ, Duncan E, Fitzpatrick D, Frier BM, Leese GP. Temporal changes in frequency of severe hypoglycemia treated by emergency medical services in types 1 and 2 diabetes: a population-based data-linkage cohort study. *Clin Diabetes Endocrinol* 2017; 3: 7

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15. <https://diabetestimes.co.uk/diabetes-nurses-group-celebrates-anniversary-2/>: Accessed 23 June 2019
 16. Lawton J, Rankin D, Cooke D, Elliott J, Amiel S, Heller S. UK NIHR DAFNE Study Group. Patients' experiences of adjusting insulin doses when implementing flexible intensive insulin therapy: a longitudinal, qualitative investigation. *Diabetes Res Clin Pract.* 2012 98: 236-42
 17. Shearer et al. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. *Diabetic Medicine* 2004; 21: 460-7
 18. Gunn, D, Mansell, P. Glycaemic control and weight seven years after DAFNE structured education in Type 1 diabetes. *Diabetic Medicine* 2012; 29: 807-12
 19. Deakin, T. The diabetes pandemic: is structured education the solution or an unnecessary expense? *Practical Diabetes* 2011, 28 NO. 8. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/pdi.1635>: Accessed 29 May 2019
 20. Jacobs-Van Der Bruggen MAM, et al. Cost-effectiveness of lifestyle modification in diabetic patients. *Diabetes Care* 2009; 32:1453–8.
 21. Gillett et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ* (2010)
 22. Davies MJ, et al. Effectiveness of the diabetes education for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial

Transparency statement

Dr Heald as the corresponding author affirms that this is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics Statement

As we used publicly available and GP level data, with no individual patient data, it was not necessary to seek Ethics Approval for this study.
This was not a clinical trial.

Funding

The relevant HES data was extracted from NHS Digital Hospital Episode Statistics by Wilmington Healthcare and provided by NAPP Pharmaceuticals.

Role of the Sponsor

There was no research sponsor for this study

Dissemination of study results to participants

Dissemination to specific participants will not be possible as all data was anonymised and at a GP practice level.

Patient Consent

This was not applicable as we analysed practice level data here.

Data Availability

In most cases publicly available data was used for the analysis. The Hospital Episode Data and filtration by Patient Diagnosis can be obtained through a suitable NHS Digital data research application. <https://digital.nhs.uk/services/data-access-request-service-dars>.

Duality of interest

No author has anything to disclose in relation to conflict of interest.

Contribution Statement

MS, MD, and AH conceived the study. MS collected the data. MS and MLu conducted the data analysis. MS, MLi, MD, AF, CD, MG, RG, SGA, GR and AH all contributed to the writing of the paper. SGA, GR, RG, AF and MG provided an overview of the manuscript.




Figure 1: Regression model results for GP practice-level prevalence of T2DM, regression factors are then be used to calculate target denominator in practice case identification %

142x105mm (400 x 400 DPI)




Figure 2A: Age Distribution and % attending hospital with age>65 for Non-Diabetes, T1DM and T2DM populations

Figure 2B: Correlation between GP practices % Non-Diabetes population Age>75 and total Non-Diabetes hospital costs/head population

120x186mm (400 x 400 DPI)




Figure 3A-E: Regression model for T2DM linking hospital costs/activity to other practice factors including age

182x211mm (400 x 400 DPI)




Figure 4: Splitting total hospital costs and activities between non-diabetes, T1DM and T2DM populations, including for impact of the T2DM age difference and DM condition

235x103mm (400 x 400 DPI)